ActiveIngredient,SubmissionType,SubmissionNo,SubmissionStatus,SubmissionStatusDate,SubmissionsPublicNotes,ReviewPriority,brand_name,ATC_A,ATC_B,ATC_C,ATC_D,ATC_G,ATC_H,ATC_J,ATC_L,ATC_M,ATC_N,ATC_P,ATC_R,ATC_S,ATC_V,description,dates,company,condition,dates_clean,approval_date,generic_name,generic_name_fw
POLIDOCANOL,ORIG,1,AP,2010-03-30T00:00:00Z,NA,STANDARD,asclera,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Asclera (polidocanol) is a sclerosing agent used for the treatment of varicose veins.,"March 30, 2010",Chemische Fabrik Kreussler & Co.,Varicose Vein,"March 30, 2010",2010-03-30,polidocanol,polidocanol
LUCINACTANT,ORIG,1,AP,2012-03-06T00:00:00Z,NA,STANDARD,surfaxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Surfaxin (lucinactant) is a synthetic, peptide-containing surfactant indicated for the prevention of respiratory distress syndrome (RDS) in premature infants.","March 6, 2012","Discovery Laboratories, Inc.",Respiratory Distress Syndrome,"March 6, 2012",2012-03-06,lucinactant,lucinactant
DEFERIPRONE,ORIG,1,AP,2011-10-14T00:00:00Z,NA,STANDARD,ferriprox,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,Ferriprox (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.,"October 14, 2011",ApoPharma Inc.,Hemosiderosis,"October 14, 2011",2011-10-14,deferiprone,deferiprone
DALBAVANCIN HYDROCHLORIDE,ORIG,1,AP,2014-05-23T00:00:00Z,NA,PRIORITY,dalvance,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Dalvance (dalbavancin) is a second generation lipoglycopeptide antibiotic for the treatment of adult patients with complicated skin and skin structure infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA).","May 23, 2014","Allergan, Inc.",Skin and Structure Infection,"May 23, 2014",2014-05-23,dalbavancin,dalbavancin
ISTRADEFYLLINE,ORIG,1,AP,2019-08-27T00:00:00Z,NA,STANDARD,nourianz,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Nourianz (istradefylline) is an adenosine A2A receptor antagonist indicated for use as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “OFF” episodes.,"August 27, 2019","Kyowa Kirin, Inc.",Parkinson's Disease,"August 27, 2019",2019-08-27,istradefylline,istradefylline
ALCAFTADINE,ORIG,1,AP,2010-07-28T00:00:00Z,NA,STANDARD,lastacaft,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,Lastacaft (alcaftadine ophthalmic solution) is a topical H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.,"July 28, 2010","Allergan, Inc.",Allergic Conjunctivitis,"July 28, 2010",2010-07-28,alcaftadine ophthalmic solution,alcaftadine
ICATIBANT ACETATE,ORIG,1,AP,2011-08-25T00:00:00Z,NA,PRIORITY,firazyr,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Firazyr (icatibant) is a selective B2 bradykinin receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema.,"August 25, 2011",Shire plc,Angioedema,"August 25, 2011",2011-08-25,icatibant,icatibant
SUGAMMADEX SODIUM,ORIG,1,AP,2015-12-15T00:00:00Z,NA,PRIORITY,bridion,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,Bridion (sugammadex) is a novel selective relaxant binding agent (SRBA) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.,"December 15, 2015","Merck & Co., Inc.",Reversal of Nondepolarizing Muscle Relaxants,"December 15, 2015",2015-12-15,sugammadex,sugammadex
"BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED",ORIG,1,AP,2013-10-03T00:00:00Z,NA,STANDARD,duavee,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Duavee (bazedoxifene and conjugated estrogens) is an estrogen
agonist/antagonist and conjugated estrogens combination indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, and prevention of postmenopausal osteoporosis in women with an intact uterus.","October 3, 2013",Pfizer Inc.,"Postmenopausal Symptoms, Prevention of Osteoporosis","October 3, 2013",2013-10-03,bazedoxifene and conjugated estrogens,bazedoxifene
DALFAMPRIDINE,ORIG,1,AP,2010-01-22T00:00:00Z,NA,PRIORITY,ampyra,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Ampyra (dalfampridine) is an oral potassium channel blocker indicated to improve walking ability in people with multiple sclerosis.,"January 22, 2010","Acorda Therapeutics, Inc.",Multiple Sclerosis,"January 22, 2010",2010-01-22,dalfampridine,dalfampridine
DIENOGEST; ESTRADIOL VALERATE,ORIG,1,AP,2010-05-06T00:00:00Z,NA,STANDARD,natazia,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Natazia (dienogest and estradiol valerate) is a combination oral contraceptive indicated for use by women to prevent pregnancy and to treat heavy menstrual bleeding.,"May 6, 2010",Bayer HealthCare Pharmaceuticals Inc.,"Contraception, Heavy Menstrual Bleeding","May 6, 2010",2010-05-06,dienogest and estradiol valerate,dienogest
ALOGLIPTIN BENZOATE,ORIG,1,AP,2013-01-25T00:00:00Z,NA,STANDARD,nesina,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes.,"January 25, 2013Company: Takeda Pharmaceutical ",Takeda Pharmaceutical Company Limited ,Diabetes Type 2,"January 25, 2013",2013-01-25,alogliptin,alogliptin
LIRAGLUTIDE RECOMBINANT,ORIG,1,AP,2010-01-25T00:00:00Z,NA,STANDARD,victoza,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.","January 25, 2010",Novo Nordisk A/S,Diabetes Type 2,"January 25, 2010",2010-01-25,liraglutide,liraglutide
EZOGABINE,ORIG,1,AP,2011-06-10T00:00:00Z,NA,STANDARD,potiga,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Potiga (ezogabine) is a potassium channel opener indicated for the adjunctive treatment of adults with partial-onset seizures.,"June 10, 2011",GlaxoSmithKline and Valeant Pharmaceuticals International,Seizures,"June 10, 2011",2011-06-10,ezogabine,ezogabine
INDACATEROL MALEATE,ORIG,1,AP,2011-07-01T00:00:00Z,NA,STANDARD,arcapta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,Arcapta (indacaterol inhalation powder) is a long-acting beta2-agonist (LABA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). ,"July 1, 2011",Novartis Pharmaceuticals Corp.,Chronic Obstructive Pulmonary Disease,"July 1, 2011",2011-07-01,indacaterol inhalation powder,indacaterol
GABAPENTIN ENACARBIL,ORIG,1,AP,2011-04-06T00:00:00Z,NA,STANDARD,horizant,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,Horizant (gabapentin enacarbil) is a  gabapentin prodrug indicated for the once-daily treatment of restless legs syndrome and postherpetic neuralgia.,"April 6, 2011","GlaxoSmithKline and XenoPort, Inc.","Restless Legs Syndrome, Postherpetic Neuralgia","April 6, 2011",2011-04-06,gabapentin enacarbil,gabapentin
VANDETANIB,ORIG,1,AP,2011-04-06T00:00:00Z,NA,PRIORITY,caprelsa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.,"April 6, 2011",AstraZeneca,Thyroid Cancer,"April 6, 2011",2011-04-06,vandetanib,vandetanib
RIVAROXABAN,ORIG,1,AP,2011-07-01T00:00:00Z,NA,STANDARD,xarelto,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Xarelto (rivaroxaban) is a factor Xa inhibitor indicated:,"July 1, 2011","Janssen Pharmaceuticals, Inc.","Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Prevention of Thromboembolism in Atrial Fibrillation, Coronary Artery Disease, Peripheral Arterial Disease, Deep Vein Thrombosis, Pulmonary Embolism","July 1, 2011",2011-07-01,rivaroxaban,rivaroxaban
SPINOSAD,ORIG,1,AP,2011-01-18T00:00:00Z,NA,STANDARD,natroba,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Natroba (spinosad) is a pediculicide indicated for the topical treatment of head lice infestations.,"January 18, 2011",ParaPRO LLC,Lice,"January 18, 2011",2011-01-18,spinosad,spinosad
ESLICARBAZEPINE ACETATE,ORIG,1,AP,2013-11-08T00:00:00Z,NA,STANDARD,aptiom,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures in patients with epilepsy.,"November 8, 2013",Sunovion Pharmaceuticals Inc.,"Epilepsy, Seizures","November 8, 2013",2013-11-08,eslicarbazepine acetate,eslicarbazepine
TICAGRELOR,ORIG,1,AP,2011-07-20T00:00:00Z,NA,STANDARD,brilinta,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Brilinta (ticagrelor) is a P2Y12 platelet inhibitor indicated to reduce the rate of 
thrombotic cardiovascular events in  patients with acute coronary syndrome.","July 20, 2011",AstraZeneca,Acute Coronary Syndrome,"July 20, 2011",2011-07-20,ticagrelor,ticagrelor
IOFLUPANE I-123,ORIG,1,AP,2011-01-14T00:00:00Z,NA,PRIORITY,datscan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"DaTscan (ioflupane I 123 injection) is a radiopharmaceutical indicated for 
striatal dopamine transporter visualization using single photon emission 
computed tomography (SPECT) brain imaging to assist in the evaluation of 
adult patients with suspected Parkinsonian syndromes (PS).","January 14, 2011",GE Healthcare,Diagnostic,"January 14, 2011",2011-01-14,ioflupane I 123 injection,ioflupane
TALIGLUCERASE ALFA,ORIG,1,AP,2012-05-01T00:00:00Z,NA,STANDARD,elelyso,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Elelyso (taliglucerase alfa) is a plant-cell expressed recombinant form of glucocerebrosidase for the treatment of Gaucher disease.,"May 1, 2012","Protalix BioTherapeutics, Inc.",Gaucher Disease,"May 1, 2012",2012-05-01,taliglucerase alfa,taliglucerase
ULIPRISTAL ACETATE,ORIG,1,AP,2010-08-13T00:00:00Z,NA,STANDARD,ella,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ,"August 13, 2010",HRA Pharma,Postcoital Contraception,"August 13, 2010",2010-08-13,NA,NA
TESAMORELIN ACETATE,ORIG,1,AP,2010-11-10T00:00:00Z,NA,STANDARD,egrifta,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Egrifta (tesamorelin) is a synthetic analogue of growth hormone releasing factor (GRF) for the treatment of excess abdominal fat in HIV patients with lipodystrophy.,"November 10, 2010",Theratechnologies,Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy,"November 10, 2010",2010-11-10,tesamorelin,tesamorelin
DABIGATRAN ETEXILATE MESYLATE,ORIG,1,AP,2010-10-19T00:00:00Z,NA,PRIORITY,pradaxa,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pradaxa (dabigatran etexilate) is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; and for the treatment and reduction of risk of deep vein thrombosis and pulmonary embolism.,"October 19, 2010","Boehringer Ingelheim Pharmaceuticals, Inc.","Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism","October 19, 2010",2010-10-19,dabigatran etexilate,dabigatran
ROFLUMILAST,ORIG,1,AP,2011-02-28T00:00:00Z,NA,STANDARD,daliresp,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,"Daliresp (roflumilast) is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor indicated as a treatment to reduce the risk of COPD  exacerbations in patients with severe COPD associated with 
chronic bronchitis and a history of exacerbations.","February 28, 2011","Allergan, Inc.",Chronic Obstructive Pulmonary Disease,"February 28, 2011",2011-02-28,roflumilast,roflumilast
FLIBANSERIN,ORIG,1,AP,2015-08-18T00:00:00Z,NA,STANDARD,addyi,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Addyi (flibanserin) is a non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of hypoactive sexual desire disorder in premenopausal women.","August 18, 2015","Sprout Pharmaceuticals, Inc.",Hypoactive Sexual Desire Disorder,"August 18, 2015",2015-08-18,flibanserin,flibanserin
FINGOLIMOD HYDROCHLORIDE,ORIG,1,AP,2010-09-21T00:00:00Z,NA,PRIORITY,gilenya,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.,"September 21, 2010",Novartis,Multiple Sclerosis,"September 21, 2010",2010-09-21,fingolimod,fingolimod
LORCASERIN HYDROCHLORIDE,ORIG,1,AP,2012-06-27T00:00:00Z,NA,STANDARD,belviq,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Belviq (lorcaserin) is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese, or overweight and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.","June 27, 2012","Arena Pharmaceuticals, Inc.",Obesity,"June 27, 2012",2012-06-27,lorcaserin,lorcaserin
PIRFENIDONE,ORIG,1,AP,2014-10-15T00:00:00Z,NA,PRIORITY,esbriet,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Esbriet (pirfenidone) is a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).,"October 15, 2014","InterMune, Inc.",Idiopathic Pulmonary Fibrosis,"October 15, 2014",2014-10-15,pirfenidone,pirfenidone
CARGLUMIC ACID,ORIG,1,AP,2010-03-18T00:00:00Z,NA,PRIORITY,carbaglu,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). ,"March 18, 2010",Orphan Europe,NAGS Deficiency Hyperammonemia,"March 18, 2010",2010-03-18,carglumic acid,carglumic
VILAZODONE HYDROCHLORIDE,ORIG,1,AP,2011-01-21T00:00:00Z,NA,STANDARD,viibryd,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD). ,"January 21, 2011","Allergan, Inc.",Depression,"January 21, 2011",2011-01-21,vilazodone,vilazodone
VELAGLUCERASE ALFA,ORIG,1,AP,2010-02-26T00:00:00Z,NA,PRIORITY,vpriv,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.,"February 26, 2010",Shire plc,Gaucher Disease,"February 26, 2010",2010-02-26,velaglucerase alfa,velaglucerase
TOCILIZUMAB,ORIG,1,AP,2010-01-08T00:00:00Z,NA,STANDARD,actemra,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment rheumatoid arthritis; systemic juvenile idiopathic arthritis (SJIA); polyarticular juvenile idiopathic arthritis (PJIA); giant cell arteritis; and CAR T cell-induced severe or life-threatening cytokine release syndrome.,"January 8, 2010","Genentech USA, Inc.","Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Giant Cell Arteritis","January 8, 2010",2010-01-08,tocilizumab,tocilizumab
BELATACEPT,ORIG,1,AP,2011-06-15T00:00:00Z,NA,STANDARD,nulojix,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Nulojix (belatacept) is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.,"June 15, 2011Company: Bristol-Myers Squibb ",Bristol-Myers Squibb Company,Organ Transplant -- Rejection Prophylaxis,"June 15, 2011",2011-06-15,belatacept,belatacept
ALGLUCOSIDASE ALFA,ORIG,1,AP,2010-05-24T00:00:00Z,NA,PRIORITY,lumizyme,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Lumizyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for patients with Pompe disease.,"May 24, 2010",Genzyme Corporation,Pompe disease,"May 24, 2010",2010-05-24,alglucosidase alfa,alglucosidase
PEGLOTICASE,ORIG,1,AP,2010-09-14T00:00:00Z,NA,PRIORITY,krystexxa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,Krystexxa (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.,"September 14, 2010","Savient Pharmaceuticals, Inc.",Gout,"September 14, 2010",2010-09-14,pegloticase,pegloticase
TBO-FILGRASTIM,ORIG,1,AP,2012-08-29T00:00:00Z,NA,STANDARD,granix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Granix (tbo-filgrastim) is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.,"August 29, 2012",Teva Pharmaceutical Industries Ltd.,Neutropenia Associated with Chemotherapy,"August 29, 2012",2012-08-29,tbo-filgrastim,tbo
DENOSUMAB,ORIG,1,AP,2010-06-01T00:00:00Z,NA,STANDARD,prolia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, for the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy, as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, and for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. ","June 1, 2010",Amgen Inc.,Osteoporosis,"June 1, 2010",2010-06-01,RANKL,RANKL
DENOSUMAB,ORIG,1,AP,2010-06-01T00:00:00Z,NA,STANDARD,xgeva,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,Xgeva (denosumab) is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Xgeva is also indicated for treatment giant cell tumor of bone and for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.,"November 18, 2010",Amgen Inc.,"Osteolytic Bone Metastases of Solid Tumors, Osteolytic Bone Lesions of Multiple Myeloma, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy","November 18, 2010",2010-11-18,denosumab,denosumab
GLUCARPIDASE,ORIG,1,AP,2012-01-17T00:00:00Z,NA,PRIORITY,voraxaze,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,Voraxaze (glucarpidase) is a carboxypeptidase enzyme indicated for the treatment of toxic plasma methotrexate levels in patients with delayed methotrexate clearance due to impaired renal function. ,"January 17, 2012",BTG International Inc.,Toxic Methotrexate Levels,"January 17, 2012",2012-01-17,glucarpidase,glucarpidase
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,ORIG,1,AP,2010-02-02T00:00:00Z,NA,PRIORITY,xiaflex,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,"Xiaflex (collagenase clostridium histolyticum) is a collagenase product for the treatment of Dupuytren's contracture, a condition that affects the connective tissue that lies beneath the skin in the palm.","February 3, 2010",BioSpecifics Technologies Corp.,Dupuytren's Contracture,"February 3, 2010",2010-02-03,collagenase clostridium histolyticum,collagenase
asparaginase Erwinia chrysanthemi,ORIG,1,AP,2011-11-18T00:00:00Z,NA,PRIORITY,erwinaze,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,Erwinaze (asparaginase Erwinia chrysanthemi) is an antineoplastic agent used to treat patients with acute lymphoblastic leukemia (ALL) who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegapargase chemotherapy drugs.,"November 18, 2011",Jazz Pharmaceuticals,Acute Lymphoblastic Leukemia,"November 18, 2011",2011-11-18,asparaginase Erwinia chrysanthemi,asparaginase
incobotulinumtoxinA,ORIG,1,AP,2010-07-30T00:00:00Z,NA,STANDARD,xeomin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Xeomin (incobotulinumtoxinA) is a botulinum toxin type A for the treatment of cervical dystonia, blepharospasm, glabellar lines, upper limb spasticity, and excessive drooling.","July 30, 2010","Merz Pharmaceuticals, LLC","Cervical Dystonia, Blepharospasm, Glabellar Lines, Upper Limb Spasticity, Excessive Salivation","July 30, 2010",2010-07-30,incobotulinumtoxinA,incobotulinumtoxinA
BELIMUMAB,ORIG,1,AP,2011-03-09T00:00:00Z,NA,PRIORITY,benlysta,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients with systemic lupus erythematosus.,"March 10, 2011","Human Genome Sciences, Inc. and GlaxoSmithKline",Systemic Lupus Erythematosus,"March 10, 2011",2011-03-10,belimumab,belimumab
IPILIMUMAB,ORIG,1,AP,2011-03-25T00:00:00Z,NA,PRIORITY,yervoy,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of melanoma. Yervoy is also used in combination with Opdivo (nivolumab) for the treatment of advanced renal cell carcinoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.","March 25, 2011",Bristol-Myers Squibb,"Melanoma -- Metastatic, Renal Cell Carcinoma, Colorectal Cancer","March 25, 2011",2011-03-25,ipilimumab,ipilimumab
AFLIBERCEPT,ORIG,1,AP,2011-11-18T00:00:00Z,NA,PRIORITY,eylea,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,"Eylea (aflibercept) is a VEGF inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.","November 18, 2011","Regeneron Pharmaceuticals, Inc.",Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetic Macular Edema,"November 18, 2011",2011-11-18,aflibercept,aflibercept
BRENTUXIMAB VEDOTIN,ORIG,1,AP,2011-08-19T00:00:00Z,NA,PRIORITY,adcetris,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,"Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) indicated for the treatment of adult patients with:
","August 19, 2011","Seattle Genetics, Inc.","Lymphoma, Hodgkin's Disease, Mycosis Fungoides","August 19, 2011",2011-08-19,brentuximab vedotin,brentuximab
METRELEPTIN,ORIG,1,AP,2014-02-24T00:00:00Z,NA,PRIORITY,myalept,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Myalept (metreleptin) is a leptin analog
indicated to treat the complications of leptin deficiency in patients with
congenital or acquired generalized lipodystrophy.","February 24, 2014","Amylin Pharmaceuticals, Inc.",Lipodystrophy,"February 24, 2014",2014-02-24,metreleptin,metreleptin
PERTUZUMAB,ORIG,1,AP,2012-06-08T00:00:00Z,NA,PRIORITY,perjeta,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Perjeta (pertuzumab) is a humanized monoclonal antibody indicated for the treatment of HER2-positive breast cancer.,"June 8, 2012",Genentech,Breast Cancer,"June 8, 2012",2012-06-08,pertuzumab,pertuzumab
ZIV-AFLIBERCEPT,ORIG,1,AP,2012-08-03T00:00:00Z,NA,PRIORITY,zaltrap,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.,"August 3, 2012","Sanofi and Regeneron Pharmaceuticals, Inc.",Colorectal Cancer,"August 3, 2012",2012-08-03,ziv-aflibercept,ziv
OCRIPLASMIN,ORIG,1,AP,2012-10-17T00:00:00Z,NA,PRIORITY,jetrea,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.,"October 17, 2012",ThromboGenics NV,Vitreomacular Adhesion,"October 17, 2012",2012-10-17,ocriplasmin,ocriplasmin
ADO-TRASTUZUMAB EMTANSINE,ORIG,1,AP,2013-02-22T00:00:00Z,NA,PRIORITY,kadcyla,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.","February 22, 2013","Genentech, Inc.",Breast Cancer,"February 22, 2013",2013-02-22,ado-trastuzumab emtansine,ado
ALBIGLUTIDE,ORIG,1,AP,2014-04-15T00:00:00Z,NA,STANDARD,tanzeum,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.,"April 15, 2014",GlaxoSmithKline (GSK) plc,Diabetes Type 2,"April 15, 2014",2014-04-15,albiglutide,albiglutide
ELOSULFASE ALFA,ORIG,1,AP,2014-02-14T00:00:00Z,NA,PRIORITY,vimizim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).,"February 14, 2014",BioMarin Pharmaceutical Inc.,Mucopolysaccharidosis Type IVA,"February 14, 2014",2014-02-14,elosufase alfa,elosufase
DULAGLUTIDE,ORIG,1,AP,2014-09-18T00:00:00Z,NA,STANDARD,trulicity,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.,"September 18, 2014Company: Eli Lilly and ",Eli Lilly and Company,Diabetes Type 2,"September 18, 2014",2014-09-18,dulaglutide,dulaglutide
VEDOLIZUMAB,ORIG,1,AP,2014-05-20T00:00:00Z,NA,PRIORITY,entyvio,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Entyvio (vedolizumab) is an integrin receptor antagonist for the treatment of Crohn's disease and ulcerative colitis. ,"May 20, 2014Company: Takeda Pharmaceutical ",Takeda Pharmaceutical Company Limited,"Crohn's Disease -- Acute, Ulcerative Colitis","May 20, 2014",2014-05-20,vedolizumab,vedolizumab
RAMUCIRUMAB,ORIG,1,AP,2014-04-21T00:00:00Z,NA,PRIORITY,cyramza,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:,"April 21, 2014Company: Eli Lilly and ",Eli Lilly and Company,"Gastric Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Hepatocellular Carcinoma","April 21, 2014",2014-04-21,ramucirumab,ramucirumab
OBINUTUZUMAB,ORIG,1,AP,2013-11-01T00:00:00Z,NA,PRIORITY,gazyva,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Gazyva (obinutuzumab) is a CD20-directed
cytolytic antibody indicated for the combination treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.","November 1, 2013",Genentech,"Chronic Lymphocytic Leukemia, Follicular Lymphoma","November 1, 2013",2013-11-01,obinutuzumab,obinutuzumab
SILTUXIMAB,ORIG,1,AP,2014-04-23T00:00:00Z,NA,PRIORITY,sylvant,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.,"April 22, 2014","Janssen Research & Development, LLC",Multicentric Castleman's Disease,"April 22, 2014",2014-04-22,siltuximab,siltuximab
PEGINTERFERON BETA-1A,ORIG,1,AP,2014-08-15T00:00:00Z,NA,STANDARD,plegridy,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.,"August 15, 2014",Biogen Idec,Multiple Sclerosis,"August 15, 2014",2014-08-15,peginterferon beta-1a,peginterferon
SECUKINUMAB,ORIG,1,AP,2015-01-21T00:00:00Z,NA,STANDARD,cosentyx,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Cosentyx (secukinumab) is a selective interleukin-17A (IL-17A) inhibitor for the treatment of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.","January 21, 2015",Novartis Pharmaceuticals Corporation,"Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis","January 21, 2015",2015-01-21,secukinumab,secukinumab
OBILTOXAXIMAB,ORIG,1,AP,2016-03-18T00:00:00Z,NA,STANDARD,anthim,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Anthim (obiltoxaximab) is a monoclonal antibody (mAb) anthrax antitoxin for the treatment and prevention of inhalational anthrax.,"March 18, 2016","Elusys Therapeutics, Inc.","Anthrax Prophylaxis, Inhalation Bacillus anthracis","March 18, 2016",2016-03-18,obiltoxaximab,obiltoxaximab
PARATHYROID HORMONE,ORIG,1,AP,2015-01-23T00:00:00Z,NA,STANDARD,natpara,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,Natpara (parathyroid hormone) is recombinant human parathyroid hormone 1-84 indicated to control hypocalcemia in patients with hypoparathyroidism.,"January 23, 2015","NPS Pharmaceuticals, Inc. ",Hypoparathyroidism,"January 23, 2015",2015-01-23,parathyroid hormone,parathyroid
ASFOTASE ALFA,ORIG,1,AP,2015-10-23T00:00:00Z,NA,PRIORITY,strensiq,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase  enzyme replacement therapy indicated for the treatment of patients with perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
","October 23, 2015","Alexion Pharmaceuticals, Inc.",Hypophosphatasia,"October 23, 2015",2015-10-23,asfotase alfa,asfotase
PEMBROLIZUMAB,ORIG,1,AP,2014-09-04T00:00:00Z,NA,PRIORITY,keytruda,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, and endometrial carcinoma.","September 4, 2014","Merck & Co., Inc.","Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Head and Neck Cancer, Hodgkin's Disease, Urothelial Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Esophageal Carcinoma, Endometrial Carcinoma","September 4, 2014",2014-09-04,pembrolizumab,pembrolizumab
DINUTUXIMAB,ORIG,1,AP,2015-03-10T00:00:00Z,NA,PRIORITY,unituxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Unituxin (dinutuximab) is a chimeric monoclonal antibody used for the treatment of pediatric neuroblastoma.,"March 10, 2015",United Therapeutics Corporation,Neuroblastoma,"March 10, 2015",2015-03-10,dinutuximab,dinutuximab
IXEKIZUMAB,ORIG,1,AP,2016-03-22T00:00:00Z,NA,STANDARD,taltz,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.","March 22, 2016Company: Eli Lilly and ",Eli Lilly and Company,"Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis","March 22, 2016",2016-03-22,ixekizumab,ixekizumab
EVOLOCUMAB,ORIG,1,AP,2015-08-27T00:00:00Z,NA,STANDARD,repatha,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Repatha (evolocumab) is a monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) indicated for the treatment of patients with heterozygous familial hypercholesterolemia; homozygous familial hypercholesterolemia; and to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. ","August 27, 2015",Amgen Inc.,High Cholesterol; Prevention of Heart Attack and Stroke,"August 27, 2015",2015-08-27,evolocumab,evolocumab
MEPOLIZUMAB,ORIG,1,AP,2015-11-04T00:00:00Z,NA,STANDARD,nucala,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,"Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients with severe eosinophilic asthma, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).","November 4, 2015",GlaxoSmithKline plc,"Asthma, Churg-Strauss Allergic Angiitis","November 4, 2015",2015-11-04,mepolizumab,mepolizumab
NECITUMUMAB,ORIG,1,AP,2015-11-24T00:00:00Z,NA,STANDARD,portrazza,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer. ,"November 24, 2015Company: Eli Lilly and ",Eli Lilly and Company,Non-Small Cell Lung Cancer,"November 24, 2015",2015-11-24,necitumumab,necitumumab
FILGRASTIM-SNDZ,ORIG,1,AP,2015-03-06T00:00:00Z,NA,STANDARD,zarxio,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,"Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.","March 6, 2015",Sandoz,Neutropenia Associated with Chemotherapy,"March 6, 2015",2015-03-06,filgrastim-sndz,filgrastim
NIVOLUMAB,ORIG,1,AP,2014-12-22T00:00:00Z,NA,PRIORITY,opdivo,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza.,"December 22, 2014Company: Bristol-Myers Squibb ",Bristol-Myers Squibb Company,"Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin's Disease, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer","December 22, 2014",2014-12-22,peramivir,peramivir
BLINATUMOMAB,ORIG,1,AP,2014-12-03T00:00:00Z,NA,PRIORITY,blincyto,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and minimal residual disease (MRD)-positive B-cell precursor ALL.","December 3, 2014",Amgen Inc.,Acute Lymphoblastic Leukemia,"December 3, 2014",2014-12-03,blinatumomab,blinatumomab
ALIROCUMAB,ORIG,1,AP,2015-07-24T00:00:00Z,NA,STANDARD,praluent,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Praluent (alirocumab) is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody indicated:,"July 24, 2015","Sanofi and Regeneron Pharmaceuticals, Inc.",High Cholesterol,"July 24, 2015",2015-07-24,alirocumab,alirocumab
SEBELIPASE ALFA,ORIG,1,AP,2015-12-08T00:00:00Z,NA,PRIORITY,kanuma,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Kanuma (sebelipase alfa) is an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D).,"December 8, 2015","Alexion Pharmaceuticals, Inc. ",Lysosomal Acid Lipase Deficiency,"December 8, 2015",2015-12-08,sebelipase alfa,sebelipase
CEFTAROLINE FOSAMIL,ORIG,1,AP,2010-10-29T00:00:00Z,NA,STANDARD,teflaro,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,Teflaro (ceftaroline fosamil) is a cephalosporin antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).,"October 29, 2010","Allergan, Inc.","Pneumonia, Skin and Structure Infection","October 29, 2010",2010-10-29,ceftaroline fosamil,ceftaroline
LURASIDONE HYDROCHLORIDE,ORIG,1,AP,2010-10-28T00:00:00Z,NA,STANDARD,latuda,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Latuda (lurasidone) is an atypical antipsychotic agent for the treatment of
schizophrenia and bipolar depression. ","October 28, 2010","Dainippon Sumitomo Pharma America, Inc.","Schizophrenia, Bipolar Disorder","October 28, 2010",2010-10-28,lurasidone,lurasidone
PASIREOTIDE DIASPARTATE,ORIG,1,AP,2012-12-14T00:00:00Z,NA,STANDARD,signifor,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.,"December 14, 2012",GlaxoSmithKline,Inhalation Bacillus anthracis,"December 14, 2012",2012-12-14,pasireotide,pasireotide
AZILSARTAN KAMEDOXOMIL,ORIG,1,AP,2011-02-25T00:00:00Z,NA,STANDARD,edarbi,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.,"February 25, 2011Company: Takeda Pharmaceutical ",Takeda Pharmaceutical Company Limited,Hypertension,"February 25, 2011",2011-02-25,azilsartan medoxomil,azilsartan
CABAZITAXEL,ORIG,1,AP,2010-06-17T00:00:00Z,NA,PRIORITY,jevtana,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.,"June 17, 2010",Sanofi-aventis,Prostate Cancer,"June 17, 2010",2010-06-17,cabazitaxel,cabazitaxel
GADOBUTROL,ORIG,1,AP,2011-03-14T00:00:00Z,NA,STANDARD,gadavist,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,Gadavist (gadobutrol) is a gadolinium-based contrast agent indicated for use in diagnostic magnetic resonance imaging (MRI).,"March 14, 2011",Bayer HealthCare Pharmaceuticals Inc.,Diagnostic,"March 14, 2011",2011-03-14,gadobutrol,gadobutrol
LINAGLIPTIN,ORIG,1,AP,2011-05-02T00:00:00Z,NA,STANDARD,tradjenta,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Tradjenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,"May 2, 2011",Boehringer Ingelheim Pharmaceuticals Inc.,Diabetes Type 2,"May 2, 2011",2011-05-02,linagliptin,linagliptin
AFATINIB DIMALEATE,ORIG,1,AP,2013-07-12T00:00:00Z,NA,PRIORITY,gilotrif,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of
patients with metastatic non-small cell lung cancer (NSCLC).","July 12, 2013",Boehringer Ingelheim Pharmaceuticals Inc.,Non-Small Cell Lung Cancer,"July 12, 2013",2013-07-12,afatinib,afatinib
ERIBULIN MESYLATE,ORIG,1,AP,2010-11-15T00:00:00Z,NA,PRIORITY,halaven,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,"Halaven (eribulin mesylate) is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer, and liposarcoma.","November 15, 2010",NA,NA,"November 15, 2010",2010-11-15,eribulin mesylate,eribulin
FIDAXOMICIN,ORIG,1,AP,2011-05-27T00:00:00Z,NA,PRIORITY,dificid,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Dificid (fidaxomicin) is a macrolide antibacterial drug indicated for the treatment of Clostridium difficile-associated diarrhea.,"May 27, 2011","Optimer Pharmaceuticals, Inc.",Clostridial Infection,"May 27, 2011",2011-05-27,fidaxomicin,fidaxomicin
TELAPREVIR,ORIG,1,AP,2011-05-23T00:00:00Z,NA,PRIORITY,incivek,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Incivek (telaprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, 
in combination with peginterferon alfa and ribavirin, for the treatment of chronic hepatitis C (CHC).","May 23, 2011",Vertex Pharmaceuticals Incorporated,Chronic Hepatitis C,"May 23, 2011",2011-05-23,telaprevir,telaprevir
FLORBETAPIR F-18,ORIG,1,AP,2012-04-06T00:00:00Z,NA,PRIORITY,amyvid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Amyvid (florbetapir F 18) is a radioactive diagnostic agent used for brain imaging of beta-amyloid plaques in patients who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.,"April 6, 2012Company: Eli Lilly and ","Eli Lilly and Company and Avid Radiopharmaceuticals, Inc.",Diagnostic,"April 6, 2012",2012-04-06,florbetapir F 18,florbetapir
RILPIVIRINE HYDROCHLORIDE,ORIG,1,AP,2011-05-20T00:00:00Z,NA,STANDARD,edurant,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naïve).,"May 20, 2011",Tibotec Pharmaceuticals,HIV Infection,"May 20, 2011",2011-05-20,rilpivirine,rilpivirine
CLOBAZAM,ORIG,1,AP,2011-10-21T00:00:00Z,NA,STANDARD,onfi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Onfi (clobazam) is a benzodiazepine antiepileptic drug for the treatment of patients with Lennox-Gastaut syndrome (LGS).,"October 21, 2011",Lundbeck Inc.,Lennox-Gastaut Syndrome,"October 21, 2011",2011-10-21,clobazam,clobazam
APIXABAN,ORIG,1,AP,2012-12-28T00:00:00Z,NA,PRIORITY,eliquis,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Eliquis (apixaban) is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery. ","December 21, 2012",Aegerion Pharmaceuticals Inc.,Homozygous Familial Hypercholesterolemia,"December 21, 2012",2012-12-21,apixaban,apixaban
RUXOLITINIB PHOSPHATE,ORIG,1,AP,2011-11-16T00:00:00Z,NA,PRIORITY,jakafi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Jakafi (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of:,"November 16, 2011",Incyte Corporation,"Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease","November 16, 2011",2011-11-16,ruxolitinib,ruxolitinib
TECHNETIUM TC-99M TILMANOCEPT,ORIG,1,AP,2013-03-13T00:00:00Z,NA,STANDARD,lymphoseek,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Lymphoseek (technetium Tc 99m tilmanocept) Injection is a radioactive
diagnostic agent indicated for lymphatic mapping in patients with breast cancer or melanoma, and for guiding sentinel lymph node
biopsy in patients with squamous cell
carcinoma of the oral cavity.","March 13, 2013",Navidea Biopharmaceuticals,Diagnostic,"March 13, 2013",2013-03-13,technetium Tc 99m tilmanocept,technetium
BOCEPREVIR,ORIG,1,AP,2011-05-13T00:00:00Z,NA,PRIORITY,victrelis,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Victrelis (boceprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C.,"May 13, 2011",Merck,Chronic Hepatitis C,"May 13, 2011",2011-05-13,boceprevir,boceprevir
AVANAFIL,ORIG,1,AP,2012-04-27T00:00:00Z,NA,STANDARD,stendra,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Stendra (avanafil) is a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).,"April 27, 2012","Vivus, Inc.",Erectile Dysfunction,"April 27, 2012",2012-04-27,avanafil,avanafil
CROFELEMER,ORIG,1,AP,2012-12-31T00:00:00Z,NA,PRIORITY,mytesi,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Mytesi (crofelemer) is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy.,"December 31, 2012","Napo Pharmaceuticals, Inc.",Diarrhea,"December 31, 2012",2012-12-31,crofelemer,crofelemer
DAPAGLIFLOZIN,ORIG,1,AP,2014-01-08T00:00:00Z,NA,STANDARD,farxiga,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Farxiga (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated:,"January 8, 2014",AstraZeneca,Diabetes Type 2,"January 8, 2014",2014-01-08,dapagliflozin,dapagliflozin
AXITINIB,ORIG,1,AP,2012-01-27T00:00:00Z,NA,STANDARD,inlyta,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. ,"January 27, 2012",Pfizer Inc.,Renal Cell Carcinoma,"January 27, 2012",2012-01-27,axitinib,axitinib
ABIRATERONE ACETATE,ORIG,1,AP,2011-04-28T00:00:00Z,NA,PRIORITY,zytiga,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,Zytiga (abiraterone acetate) is a CYP17 inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.,"April 28, 2011",Centocor Ortho Biotech Inc.,Prostate Cancer,"April 28, 2011",2011-04-28,abiraterone acetate,abiraterone
VEMURAFENIB,ORIG,1,AP,2011-08-17T00:00:00Z,NA,PRIORITY,zelboraf,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Zelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients 
with metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, and for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.","August 17, 2011","Genentech, Inc.",Melanoma -- Metastatic,"August 17, 2011",2011-08-17,vemurafenib,vemurafenib
ACLIDINIUM BROMIDE,ORIG,1,AP,2012-07-23T00:00:00Z,NA,STANDARD,tudorza,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ","July 23, 2012","Allergan, Inc.",Chronic Obstructive Pulmonary Disease,"July 23, 2012",2012-07-23,aclidinium bromide inhalation powder,aclidinium
TAFLUPROST,ORIG,1,AP,2012-02-10T00:00:00Z,NA,STANDARD,zioptan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,"February 10, 2012","Merck & Co., Inc.","Glaucoma (Open Angle), Intraocular Hypertension","February 10, 2012",2012-02-10,tafluprost ophthalmic solution,tafluprost
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE,ORIG,1,AP,2012-07-16T00:00:00Z,NA,STANDARD,prepopik,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Prepopik (sodium picosulfate, magnesium oxide and citric acid) is a stimulant laxative and osmotic laxative combination indicated for cleansing of the colon as a preparation for colonoscopy in adults.","July 16, 2012",Ferring Pharmaceuticals,Bowel Preparation,"July 16, 2012",2012-07-16,"sodium picosulfate, magnesium oxide and citric acid",sodium
CRIZOTINIB,ORIG,1,AP,2011-08-26T00:00:00Z,NA,PRIORITY,xalkori,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Xalkori (crizotinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive or ROS1-positive.,"August 26, 2011",Pfizer Inc.,Non-Small Cell Lung Cancer,"August 26, 2011",2011-08-26,crizotinib,crizotinib
MIRABEGRON,ORIG,1,AP,2012-06-28T00:00:00Z,NA,STANDARD,myrbetriq,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.","June 28, 2012",Astellas Pharma Inc.,Overactive Bladder,"June 28, 2012",2012-06-28,mirabegron,mirabegron
CARFILZOMIB,ORIG,1,AP,2012-07-20T00:00:00Z,NA,STANDARD,kyprolis,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Kyprolis (carfilzomib) is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma.,"July 20, 2012",Amgen Inc.,Multiple Myeloma,"July 20, 2012",2012-07-20,carfilzomib,carfilzomib
PEGINESATIDE ACETATE,ORIG,1,AP,2012-03-27T00:00:00Z,NA,STANDARD,omontys,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Omontys (peginesatide) an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.,"March 27, 2012Company: Affymax, Inc. and Takeda Pharmaceutical ","Affymax, Inc. and Takeda Pharmaceutical Company Limited",Anemia Associated with Chronic Renal Failure,"March 27, 2012",2012-03-27,peginesatide,peginesatide
DABRAFENIB MESYLATE,ORIG,1,AP,2013-05-29T00:00:00Z,NA,STANDARD,tafinlar,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Tafinlar (dabrafenib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.,"May 29, 2013",GlaxoSmithKline,"Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Thyroid Cancer","May 29, 2013",2013-05-29,dabrafenib,dabrafenib
LINACLOTIDE,ORIG,1,AP,2012-08-30T00:00:00Z,NA,STANDARD,linzess,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Linzess (linaclotide) is a guanylate cyclase-C agonist indicated in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).,"August 30, 2012","Allergan, Inc.","Irritable Bowel Syndrome, Constipation -- Chronic","August 30, 2012",2012-08-30,linaclotide,linaclotide
INGENOL MEBUTATE,ORIG,1,AP,2012-01-23T00:00:00Z,NA,STANDARD,picato,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Picato (ingenol mebutate) is an inducer of cell death indicated for the topical treatment of actinic keratosis.,"January 23, 2012",Leo Pharma,Actinic Keratosis,"January 23, 2012",2012-01-23,ingenol mebutate,ingenol
PERAMPANEL,ORIG,1,AP,2012-10-22T00:00:00Z,NA,STANDARD,fycompa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist indicated for the treatment of partial-onset seizures, and as adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy.","October 22, 2012",Eisai Inc.,"Epilepsy, Seizures","October 22, 2012",2012-10-22,perampanel,perampanel
TERIFLUNOMIDE,ORIG,1,AP,2012-09-12T00:00:00Z,NA,STANDARD,aubagio,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Aubagio (teriflunomide) is an oral pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.,"September 12, 2012",Sanofi,Multiple Sclerosis,"September 12, 2012",2012-09-12,teriflunomide,teriflunomide
REGORAFENIB,ORIG,1,AP,2012-09-27T00:00:00Z,NA,PRIORITY,stivarga,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Stivarga (regorafenib) is an oral multi-kinase inhibitor for the treatment of
patients with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.","September 27, 2012",Bayer HealthCare Pharmaceuticals Inc.,"Colorectal Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma","September 27, 2012",2012-09-27,regorafenib,regorafenib
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE,ORIG,1,AP,2012-08-27T00:00:00Z,NA,STANDARD,stribild,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,"Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults. ","August 27, 2012","Gilead Sciences, Inc.",HIV Infection,"August 27, 2012",2012-08-27,"cobicistat, elvitegravir, emtricitabine and tenofovir",cobicistat
OLODATEROL HYDROCHLORIDE,ORIG,1,AP,2014-07-31T00:00:00Z,NA,STANDARD,striverdi respimat,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,"Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).","July 31, 2014",Boehringer Ingelheim Pharmaceuticals Inc.,Chronic Obstructive Pulmonary Disease,"July 31, 2014",2014-07-31,olodaterol,olodaterol
FLUTEMETAMOL F-18,ORIG,1,AP,2013-10-25T00:00:00Z,NA,STANDARD,vizamyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease or other cognitive disorders. ,"October 25, 2013",GE Healthcare,Diagnostic,"October 25, 2013",2013-10-25,flutemetamol F 18,flutemetamol
IVACAFTOR,ORIG,1,AP,2012-01-31T00:00:00Z,NA,PRIORITY,kalydeco,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients ages 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor.,"January 31, 2012",Vertex Pharmaceuticals Incorporated,Cystic Fibrosis,"January 31, 2012",2012-01-31,ivacaftor,ivacaftor
DROXIDOPA,ORIG,1,AP,2014-02-18T00:00:00Z,NA,PRIORITY,northera,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Northera (droxidopa) is an orally active synthetic precursor of norepinephrine indicated for the treatment of neurogenic orthostatic hypotension.,"February 18, 2014","Chelsea Therapeutics International, Ltd.",Neurogenic Orthostatic Hypotension,"February 18, 2014",2014-02-18,droxidopa,droxidopa
TOFACITINIB CITRATE,ORIG,1,AP,2012-11-06T00:00:00Z,NA,STANDARD,xeljanz,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis.","November 6, 2012",Pfizer Inc.,"Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis","November 6, 2012",2012-11-06,tofacitinib,tofacitinib
INSULIN ASPART; INSULIN DEGLUDEC,ORIG,1,AP,2015-09-25T00:00:00Z,NA,STANDARD,ryzodeg 70/30,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Ryzodeg 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus. ,"September 25, 2015",Novo Nordisk,"Diabetes Type 1, Diabetes Type 2","September 25, 2015",2015-09-25,insulin degludec and insulin aspart,insulin
INSULIN DEGLUDEC,ORIG,1,AP,2015-09-25T00:00:00Z,NA,STANDARD,tresiba,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients one year of age and older with diabetes mellitus.,"September 25, 2015",Novo Nordisk,"Diabetes Type 1, Diabetes Type 2","September 25, 2015",2015-09-25,insulin degludec,insulin
BOSUTINIB MONOHYDRATE,ORIG,1,AP,2012-09-04T00:00:00Z,NA,STANDARD,bosulif,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Bosulif (bosutinib) is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML). ","September 4, 2012",Pfizer Inc.,Chronic Myelogenous Leukemia,"September 4, 2012",2012-09-04,bosutinib,bosutinib
VISMODEGIB,ORIG,1,AP,2012-01-30T00:00:00Z,NA,PRIORITY,erivedge,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell carcinoma (BCC).,"January 30, 2012",Genentech,Basal Cell Carcinoma,"January 30, 2012",2012-01-30,vismodegib,vismodegib
ENZALUTAMIDE,ORIG,1,AP,2012-08-31T00:00:00Z,NA,PRIORITY,xtandi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer.","August 31, 2012",Astellas Pharma Inc.,Prostate Cancer,"August 31, 2012",2012-08-31,enzalutamide,enzalutamide
TEDUGLUTIDE RECOMBINANT,ORIG,1,AP,2012-12-21T00:00:00Z,NA,STANDARD,gattex,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Gattex (teduglutide) is a recombinant analog of human glucagon-like peptide 2 for the treatment of short bowel syndrome in adults and pediatric patients one year of age and older.,"December 21, 2012",Biotest Pharmaceuticals Corporation,Primary Immunodeficiency Syndrome,"December 21, 2012",2012-12-21,teduglutide,teduglutide
PONATINIB HYDROCHLORIDE,ORIG,1,AP,2012-12-14T00:00:00Z,NA,PRIORITY,iclusig,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Iclusig (ponatinib) is a kinase inhibitor  for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).,"December 14, 2012","Ariad Pharmaceuticals, Inc.","Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia","December 14, 2012",2012-12-14,ponatinib,ponatinib
OSPEMIFENE,ORIG,1,AP,2013-02-26T00:00:00Z,NA,STANDARD,osphena,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Osphena (ospemifene) is an estrogen agonist/antagonist indicated for the treatment of symptoms of vulvar and vaginal atrophy due to menopause, including severe dyspareunia and moderate to severe vaginal dryness.","February 26, 2013",Duchesnay Inc.,"Dyspareunia, Atrophic Vaginitis","February 26, 2013",2013-02-26,ospemifene,ospemifene
EFINACONAZOLE,ORIG,1,AP,2014-06-06T00:00:00Z,NA,STANDARD,jublia,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Jublia (efinaconazole) is a topical triazole antifungal for the treatment of onychomycosis of the toenails.,"June 6, 2014","Valeant Pharmaceuticals International, Inc.",Onychomycosis -- Toenail,"June 6, 2014",2014-06-06,efinaconazole,efinaconazole
MIPOMERSEN SODIUM,ORIG,1,AP,2013-01-29T00:00:00Z,NA,STANDARD,kynamro,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Kynamro (mipomersen) is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated for the treatment of patients with homozygous familial hypercholesterolemia.,"January 29, 2013",Kastle Therapeutics,Homozygous Familial Hypercholesterolemia,"January 29, 2013",2013-01-29,mipomersen,mipomersen
OMACETAXINE MEPESUCCINATE,ORIG,1,AP,2012-10-26T00:00:00Z,NA,STANDARD,synribo,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,Synribo (omacetaxine mepesuccinate) is a first-in-class small molecule drug for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia.,"October 26, 2012",Teva Pharmaceuticals,Chronic Myelogenous Leukemia,"October 26, 2012",2012-10-26,omacetaxine mepesuccinate,omacetaxine
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES,ORIG,1,AP,2014-10-10T00:00:00Z,NA,STANDARD,lumason,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Lumason (sulfur hexafluoride lipid microsphere) is a contrast agent used for ultrasound imaging.,"October 10, 2014",Bracco Diagnostics Inc.,Diagnostic,"October 10, 2014",2014-10-10,sulfur hexafluoride lipid microsphere,sulfur
CABOZANTINIB S-MALATE,ORIG,1,AP,2012-11-29T00:00:00Z,NA,PRIORITY,cometriq,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.","November 29, 2012","Exelixis, Inc.",Thyroid Cancer,"November 29, 2012",2012-11-29,cabozantinib,cabozantinib
LOMITAPIDE MESYLATE,ORIG,1,AP,2012-12-21T00:00:00Z,NA,STANDARD,juxtapid,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor indicated for the treatment of patients with homozygous familial hypercholesterolemia.,"December 20, 2012",Cangene Corporation,Varicella-Zoster,"December 20, 2012",2012-12-20,lomitapide,lomitapide
RADIUM RA-223 DICHLORIDE,ORIG,1,AP,2013-05-15T00:00:00Z,NA,PRIORITY,xofigo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Xofigo (radium 223 dichloride) is an alpha
particle-emitting radioactive therapeutic
agent indicated for the treatment of
patients with castration-resistant prostate cancer.","May 15, 2013",Bayer HealthCare Pharmaceuticals Inc.,Prostate Cancer,"May 15, 2013",2013-05-15,radium 223 dichloride,radium
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE,ORIG,1,AP,2013-12-18T00:00:00Z,NA,STANDARD,anoro ellipta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Anoro Ellipta (umeclidinium bromide and vilanterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) combination for the treatment of COPD.,"December 18, 2013","GlaxoSmithKline plc (GSK) and Theravance, Inc.",Chronic Obstructive Pulmonary Disease,"December 18, 2013",2013-12-18,umeclidinium bromide and vilanterol,umeclidinium
POMALIDOMIDE,ORIG,1,AP,2013-02-08T00:00:00Z,NA,PRIORITY,pomalyst,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma.,"February 8, 2013",Celgene Corporation,Multiple Myeloma,"February 8, 2013",2013-02-08,pomalidomide,pomalidomide
CANAGLIFLOZIN,ORIG,1,AP,2013-03-29T00:00:00Z,NA,STANDARD,invokana,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Invokana (canagliflozin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor indicated:,"March 29, 2013","Janssen Research & Development, LLC","Diabetes Type 2, Cardiovascular Risk Reduction, Diabetic Nephropathy","March 29, 2013",2013-03-29,canagliflozin,canagliflozin
DIMETHYL FUMARATE,ORIG,1,AP,2013-03-27T00:00:00Z,NA,STANDARD,tecfidera,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,Tecfidera (dimethyl fumarate) is an oral Nrf2 pathway activator for the treatment of relapsing forms of multiple sclerosis.,"March 27, 2013",Biogen Idec,Multiple Sclerosis,"March 27, 2013",2013-03-27,dimethyl fumarate,dimethyl
TRAMETINIB DIMETHYL SULFOXIDE,ORIG,1,AP,2013-05-29T00:00:00Z,NA,STANDARD,mekinist,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Mekinist (trametinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.,"May 29, 2013",GlaxoSmithKline,"Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Thyroid Cancer","May 29, 2013",2013-05-29,trametinib,trametinib
LULICONAZOLE,ORIG,1,AP,2013-11-14T00:00:00Z,NA,STANDARD,luzu,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Luzu (luliconazole) Cream  is an azole antifungal indicated for the
topical treatment of interdigital tinea
pedis, tinea cruris, and tinea corporis. ","November 14, 2013","Valeant Pharmaceuticals International, Inc.","Tinea Corporis, Tinea Pedis, Tinea Cruris","November 14, 2013",2013-11-14,luliconazole,luliconazole
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE,ORIG,1,AP,2013-05-10T00:00:00Z,NA,STANDARD,breo ellipta,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist (LABA) combination indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma.,"May 10, 2013","GlaxoSmithKline plc (GSK) and Theravance, Inc.","Chronic Obstructive Pulmonary Disease, Asthma","May 10, 2013",2013-05-10,fluticasone and vilanterol,fluticasone
CARIPRAZINE HYDROCHLORIDE,ORIG,1,AP,2015-09-17T00:00:00Z,NA,STANDARD,vraylar,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Vraylar (cariprazine) is a dopamine D3/D2 receptor partial
agonist atypical antipsychotic for the:","September 17, 2015",Allergan and Gedeon Richter plc,"Schizophrenia, Bipolar Disorder","September 17, 2015",2015-09-17,cariprazine,cariprazine
BEDAQUILINE FUMARATE,ORIG,1,AP,2012-12-28T00:00:00Z,NA,PRIORITY,sirturo,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Sirturo (bedaquiline) is an oral diarylquinoline antimycobacterial drug indicated for the treatment of pulmonary multi-drug resistant tuberculosis.,"December 28, 2012","Janssen Research & Development, LLC",Tuberculosis -- Resistant,"December 28, 2012",2012-12-28,bedaquiline,bedaquiline
MACITENTAN,ORIG,1,AP,2013-10-18T00:00:00Z,NA,STANDARD,opsumit,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Opsumit (macitentan) is a dual endothelin receptor antagonist for the treatment of patients with pulmonary arterial hypertension.,"October 18, 2013",Actelion Pharmaceuticals Ltd.,Pulmonary Hypertension,"October 18, 2013",2013-10-18,macitentan,macitentan
TAVABOROLE,ORIG,1,AP,2014-07-07T00:00:00Z,NA,STANDARD,kerydin,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Kerydin (tavaborole) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails.,"July 7, 2014",Anacor Pharmaceuticals,Onychomycosis -- Toenail,"July 7, 2014",2014-07-07,tavaborole,tavaborole
VORTIOXETINE HYDROBROMIDE,ORIG,1,AP,2013-09-30T00:00:00Z,NA,STANDARD,trintellix,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Trintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).,"September 30, 2013Company: Takeda Pharmaceutical ",Takeda Pharmaceutical Company Limited and H. Lundbeck A/S,Depression,"September 30, 2013",2013-09-30,vortioxetine,vortioxetine
SUVOREXANT,ORIG,1,AP,2014-08-13T00:00:00Z,NA,STANDARD,belsomra,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Belsomra (suvorexant) is an orexin receptor antagonist for use in patients with difficulty falling or staying asleep (insomnia).,"August 13, 2014","Merck, Sharpe & Dohme Corp.",Insomnia,"August 13, 2014",2014-08-13,suvorexant,suvorexant
EMPAGLIFLOZIN,ORIG,1,AP,2014-08-01T00:00:00Z,NA,STANDARD,jardiance,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults
with type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.","August 1, 2014","Boehringer Ingelheim Pharmaceuticals, Inc.",Diabetes Type 2,"August 1, 2014",2014-08-01,empagliflozin,empagliflozin
SOFOSBUVIR,ORIG,1,AP,2013-12-06T00:00:00Z,NA,PRIORITY,sovaldi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Sovaldi (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of:,"December 6, 2013",Gilead Sciences,Chronic Hepatitis C,"December 6, 2013",2013-12-06,sofosbuvir,sofosbuvir
FLORBETABEN F-18,ORIG,1,AP,2014-03-19T00:00:00Z,NA,STANDARD,neuraceq,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Neuraceq (florbetaben F18) is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaquedensity in adult patients with cognitive impairment who are being evaluated
for Alzheimer’s Disease (AD) and other causes of cognitive decline.","March 19, 2014",Piramal Imaging,Positron Emission Tomography Imaging,"March 19, 2014",2014-03-19,florbetaben F18,florbetaben
MILTEFOSINE,ORIG,1,AP,2014-03-19T00:00:00Z,NA,PRIORITY,impavido,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.,"March 19, 2014",Paladin Labs Inc. ,Leishmaniasis,"March 19, 2014",2014-03-19,miltefosine,miltefosine
NALOXEGOL OXALATE,ORIG,1,AP,2014-09-16T00:00:00Z,NA,STANDARD,movantik,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Movantik (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation.,"September 16, 2014",AstraZeneca Pharmaceuticals LP,Opioid-Induced Constipation,"September 16, 2014",2014-09-16,naloxegol,naloxegol
GADOTERATE MEGLUMINE,ORIG,1,AP,2013-03-20T00:00:00Z,NA,PRIORITY,dotarem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Dotarem (gadoterate meglumine) is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI).,"March 20, 2013",Guerbet,Diagnostic,"March 20, 2013",2013-03-20,gadoterate meglumine,gadoterate
DOLUTEGRAVIR SODIUM,ORIG,1,AP,2013-08-12T00:00:00Z,NA,PRIORITY,tivicay,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Tivicay (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.,"August 12, 2013",ViiV Healthcare,HIV Infection,"August 12, 2013",2013-08-12,dolutegravir,dolutegravir
RIOCIGUAT,ORIG,1,AP,2013-10-08T00:00:00Z,NA,STANDARD,adempas,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Adempas (riociguat) is an oral soluble guanylate cyclase (sGC) stimulator for the treatment of pulmonary hypertension.,"October 8, 2013",Bayer HealthCare Pharmaceuticals Inc.,Pulmonary Hypertension,"October 8, 2013",2013-10-08,riociguat,riociguat
VORAPAXAR SULFATE,ORIG,1,AP,2014-05-08T00:00:00Z,NA,STANDARD,zontivity,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients.,"May 8, 2014",Merck,Cardiovascular Risk Reduction,"May 8, 2014",2014-05-08,vorapaxar,vorapaxar
CANGRELOR,ORIG,1,AP,2015-06-22T00:00:00Z,NA,STANDARD,kengreal,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Kengreal (cangrelor) is an intravenous P2Y12 platelet inhibitor indicated for use in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of periprocedural thrombotic events.,"June 22, 2015Company: The Medicines ",The Medicines Company,Percutaneous Coronary Intervention,"June 22, 2015",2015-06-22,cangrelor,cangrelor
SIMEPREVIR SODIUM,ORIG,1,AP,2013-11-22T00:00:00Z,NA,PRIORITY,olysio,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Olysio (simeprevir) is a protease inhibitor for the treatment of chronic hepatitis C virus infection.,"November 22, 2013","Janssen Research & Development, LLC",Chronic Hepatitis C,"November 22, 2013",2013-11-22,simeprevir,simeprevir
SONIDEGIB PHOSPHATE,ORIG,1,AP,2015-07-24T00:00:00Z,NA,STANDARD,odomzo,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).,"July 24, 2015",Novartis Pharmaceuticals Corporation,Basal Cell Carcinoma,"July 24, 2015",2015-07-24,sonidegib,sonidegib
PANOBINOSTAT LACTATE,ORIG,1,AP,2015-02-23T00:00:00Z,NA,PRIORITY,farydak,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.,"February 23, 2015",Novartis Pharmaceuticals Corporation,Multiple Myeloma,"February 23, 2015",2015-02-23,panobinostat,panobinostat
BREXPIPRAZOLE,ORIG,1,AP,2015-07-10T00:00:00Z,NA,STANDARD,rexulti,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Rexulti (brexpiprazole) is a serotonin-dopamine activity modulator (SDAM) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder.,"July 10, 2015","Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S",Schizophrenia; Major Depressive Disorder,"July 10, 2015",2015-07-10,brexpiprazole,brexpiprazole
TEDIZOLID PHOSPHATE,ORIG,1,AP,2014-06-20T00:00:00Z,NA,PRIORITY,sivextro,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic drug indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).,"June 20, 2014","Cubist Pharmaceuticals, Inc.",Skin and Structure Infection,"June 20, 2014",2014-06-20,tedizolid phosphate,tedizolid
APREMILAST,ORIG,1,AP,2014-03-21T00:00:00Z,NA,STANDARD,otezla,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s Disease.","March 21, 2014",Celgene Corporation,"Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease","March 21, 2014",2014-03-21,apremilast,apremilast
ELIGLUSTAT TARTRATE,ORIG,1,AP,2014-08-19T00:00:00Z,NA,PRIORITY,cerdelga,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long-
term treatment of adult patients with
Gaucher disease type 1.","August 19, 2014",Genzyme Corporation,Gaucher Disease,"August 19, 2014",2014-08-19,eliglustat,eliglustat
IBRUTINIB,ORIG,1,AP,2013-11-13T00:00:00Z,NA,PRIORITY,imbruvica,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease.","November 13, 2013","Janssen Biotech, Inc.",Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenström’s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Chronic Graft Versus Host Disease,"November 13, 2013",2013-11-13,ibrutinib,ibrutinib
MACIMORELIN ACETATE,ORIG,1,AP,2017-12-20T00:00:00Z,NA,STANDARD,macrilen,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,Macrilen (macimorelin) is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency.,"December 20, 2017",Aeterna Zentaris Inc.,Diagnosis of Adult Growth Hormone Deficiency,"December 20, 2017",2017-12-20,macimorelin,macimorelin
TASIMELTEON,ORIG,1,AP,2014-01-31T00:00:00Z,NA,PRIORITY,hetlioz,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Hetlioz (tasimelteon) is a melatonin receptor agonist for the treatment of Non-24-Hour Disorder in the totally blind.,"January 31, 2014",Vanda Pharmaceuticals Inc.,Non-24-Hour Disorder,"January 31, 2014",2014-01-31,tasimelteon,tasimelteon
NETUPITANT; PALONOSETRON HYDROCHLORIDE,ORIG,1,AP,2014-10-10T00:00:00Z,NA,STANDARD,akynzeo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Akynzeo (netupitant and palonosetron) is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).,"October 10, 2014",Helsinn Group,Nausea/Vomiting -- Chemotherapy Induced,"October 10, 2014",2014-10-10,netupitant and palonosetron,netupitant
PATIROMER SORBITEX CALCIUM,ORIG,1,AP,2015-10-21T00:00:00Z,NA,STANDARD,veltassa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Veltassa (patiromer) is an oral potassium binder for the treatment of hyperkalemia. ,"October 21, 2015","Relypsa, Inc. ",Hyperkalemia,"October 21, 2015",2015-10-21,patiromer,patiromer
CHOLIC ACID,ORIG,1,AP,2015-03-17T00:00:00Z,NA,PRIORITY,cholbam,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cholbam (cholic acid) is a bile acid preparation for the treatment of patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders).","March 17, 2015",Asklepion Pharmaceuticals LLC,Bile Acid Synthesis Disorders,"March 17, 2015",2015-03-17,cholic acid,cholic
CERITINIB,ORIG,1,AP,2014-04-29T00:00:00Z,NA,PRIORITY,zykadia,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.,"April 29, 2014",Novartis Pharmaceuticals Corporation,Non-Small Cell Lung Cancer,"April 29, 2014",2014-04-29,ceritinib,ceritinib
NINTEDANIB ESYLATE,ORIG,1,AP,2014-10-15T00:00:00Z,NA,PRIORITY,ofev,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Ofev (nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) indicated for the treatment of idiopathic pulmonary fibrosis, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).","October 15, 2014","Boehringer Ingelheim Pharmaceuticals, Inc.",Idiopathic Pulmonary Fibrosis; Sclerosis-Associated Interstitial Lung Disease,"October 15, 2014",2014-10-15,nintedanib,nintedanib
LEDIPASVIR; SOFOSBUVIR,ORIG,1,AP,2014-10-10T00:00:00Z,NA,PRIORITY,harvoni,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Harvoni (ledipasvir and sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus
(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older:","October 10, 2014","Gilead Sciences, Inc.",Chronic Hepatitis C,"October 10, 2014",2014-10-10,ledipasvir and sofosbuvir,ledipasvir
BRIVARACETAM,ORIG,1,AP,2016-02-18T00:00:00Z,"FR Notice on DEA Scheduling; Date of Approval  May 12, 2016",STANDARD,briviact,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.","February 19, 2016","UCB, Inc.",Epilepsy,"February 19, 2016",2016-02-19,brivaracetam,brivaracetam
IDELALISIB,ORIG,1,AP,2014-07-23T00:00:00Z,NA,STANDARD,zydelig,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.","July 23, 2014","Gilead Sciences, Inc.","non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma","July 23, 2014",2014-07-23,idelalisib,idelalisib
IVACAFTOR; LUMACAFTOR,ORIG,1,AP,2015-07-02T00:00:00Z,NA,PRIORITY,orkambi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,Orkambi (ivacaftor and lumacaftor) is a CFTR potentiator and CFTR corrector combination for the treatment of the underlying cause of cystic fibrosis in patients 2 years and older with two copies of the F508del mutation in their CFTR gene.,"July 2, 2015",Vertex Pharmaceuticals Incorporated,Cystic Fibrosis,"July 2, 2015",2015-07-02,ivacaftor and lumacaftor,ivacaftor
IVABRADINE HYDROCHLORIDE,ORIG,1,AP,2015-04-15T00:00:00Z,NA,PRIORITY,corlanor,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.,"April 15, 2015",Amgen Inc.,Chronic Heart Failure,"April 15, 2015",2015-04-15,ivabradine,ivabradine
OLAPARIB,ORIG,1,AP,2014-12-19T00:00:00Z,NA,PRIORITY,lynparza,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A
protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.","December 19, 2014",AstraZeneca,"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreatic Cancer","December 19, 2014",2014-12-19,ombitasvir/paritaprevir/ritonavir with dasabuvir,ombitasvir
COBIMETINIB FUMARATE,ORIG,1,AP,2015-11-10T00:00:00Z,NA,PRIORITY,cotellic,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Cotellic (cobimetinib) is a kinase inhibitor indicated for use in combination with vemurafenib for the treatment of advanced melanoma with a BRAF V600E or V600K mutation.,"November 10, 2015","Genentech, Inc.",Melanoma -- Metastatic,"November 10, 2015",2015-11-10,cobimetinib,cobimetinib
BELINOSTAT,ORIG,1,AP,2014-07-03T00:00:00Z,NA,PRIORITY,beleodaq,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).,"July 3, 2014","Spectrum Pharmaceuticals, Inc.",Peripheral T-cell Lymphoma,"July 3, 2014",2014-07-03,belinostat,belinostat
FINAFLOXACIN,ORIG,1,AP,2014-12-17T00:00:00Z,NA,PRIORITY,xtoro,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Xtoro (finafloxacin otic suspension) is a fluoroquinolone antimicrobial for the treatment of acute otitis externa, commonly known as swimmer’s ear.","December 17, 2014","Alcon Laboratories, Inc.",Otitis Externa,"December 17, 2014",2014-12-17,finafloxacin otic suspension,finafloxacin
EDOXABAN TOSYLATE,ORIG,1,AP,2015-01-08T00:00:00Z,NA,STANDARD,savaysa,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Savaysa (edoxaban) is an oral, once-daily factor Xa inhibitor anticoagulant indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis, and pulmonary embolism.","January 8, 2015Company: Daiichi Sankyo ",Daiichi Sankyo Company,"Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism","January 8, 2015",2015-01-08,edoxaban,edoxaban
DEOXYCHOLIC ACID,ORIG,1,AP,2015-04-29T00:00:00Z,NA,STANDARD,kybella,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Kybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin).,"April 29, 2015","Allergan, Inc.",Submental Fullness,"April 29, 2015",2015-04-29,deoxycholic acid,deoxycholic
ORITAVANCIN DIPHOSPHATE,ORIG,1,AP,2014-08-06T00:00:00Z,NA,PRIORITY,orbactiv,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Orbactiv (oritavancin) is a semi-synthetic lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).,"August 6, 2014Company: The Medicines ",The Medicines Company,Skin and Structure Infection,"August 6, 2014",2014-08-06,oritavancin,oritavancin
PERAMIVIR,ORIG,1,AP,2014-12-19T00:00:00Z,NA,STANDARD,rapivab,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,Soolantra (ivermectin) is a topical antiparasitic with anti-inflammatory properties for the treatment of rosacea potentially caused by the microscopic skin mite Demodex folliculorum.,"December 19, 2014","BioCryst Pharmaceuticals, Inc.",Influenza,"December 19, 2014",2014-12-19,ivermectin,ivermectin
ETEPLIRSEN,ORIG,1,AP,2016-09-19T00:00:00Z,NA,PRIORITY,exondys 51,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,"Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of
Duchenne muscular dystrophy (DMD) in patients who have a confirmed
mutation of the DMD gene that is amenable to exon 51 skipping.","September 19, 2016",Sarepta Therapeutics,Duchenne Muscular Dystrophy,"September 19, 2016",2016-09-19,eteplirsen,eteplirsen
AVIBACTAM SODIUM; CEFTAZIDIME,ORIG,1,AP,2015-02-25T00:00:00Z,NA,PRIORITY,avycaz,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Avycaz (avibactam and ceftazidime) is a next generation, non-β lactam β-lactamase inhibitor and third-generation, antipseudomonal cephalosporin antibiotic combination for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia.","February 25, 2015",Actavis plc,"Intraabdominal Infection, Urinary Tract Infection, Pneumonia","February 25, 2015",2015-02-25,avibactam and ceftazidime,avibactam
ROLAPITANT HYDROCHLORIDE,ORIG,1,AP,2015-09-01T00:00:00Z,NA,STANDARD,varubi,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.,"September 1, 2015",Tesaro Inc.,Nausea/Vomiting -- Chemotherapy Induced,"September 1, 2015",2015-09-01,rolapitant,rolapitant
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR,ORIG,1,AP,2014-12-19T00:00:00Z,NA,PRIORITY,viekira pak,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Zerbaxa (ceftolozane and tazobactam) is a cephalosporin and beta-lactamase inhibitor combination for the treatment of:,"December 19, 2014",AbbVie Inc.,Chronic Hepatitis C,"December 19, 2014",2014-12-19,ceftolozane and tazobactam,ceftolozane
STIRIPENTOL,ORIG,1,AP,2018-08-20T00:00:00Z,NA,PRIORITY,diacomit,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.,"August 20, 2018",Biocodex,Dravet Syndrome,"August 20, 2018",2018-08-20,stiripentol,stiripentol
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE,ORIG,1,AP,2015-05-21T00:00:00Z,NA,STANDARD,stiolto respimat,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).,"May 21, 2015","Boehringer Ingelheim Pharmaceuticals, Inc.",Chronic Obstructive Pulmonary Disease,"May 21, 2015",2015-05-21,olodaterol and tiotropium bromide,olodaterol
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM,ORIG,1,AP,2014-12-19T00:00:00Z,NA,PRIORITY,zerbaxa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of advanced melanoma, advanced non-small cell lung cancer, advanced small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, advanced squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, and hepatocellular carcinoma.","December 19, 2014","Cubist Pharmaceuticals, Inc.","Intraabdominal Infection, Urinary Tract Infection, Pneumonia","December 19, 2014",2014-12-19,nivolumab,nivolumab
DACLATASVIR DIHYDROCHLORIDE,ORIG,1,AP,2015-07-24T00:00:00Z,NA,PRIORITY,daklinza,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Daklinza (daclatasvir) is an NS5A inhibitor indicated for use in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.,"July 24, 2015Company: Bristol-Myers Squibb ",Bristol-Myers Squibb Company,Chronic Hepatitis C,"July 24, 2015",2015-07-24,daclatasvir,daclatasvir
ELUXADOLINE,ORIG,1,AP,2015-05-27T00:00:00Z,NA,PRIORITY,viberzi,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. ,"May 27, 2015","Allergan, Inc.",Irritable Bowel Syndrome,"May 27, 2015",2015-05-27,eluxadoline,eluxadoline
LENVATINIB MESYLATE,ORIG,1,AP,2015-02-13T00:00:00Z,NA,PRIORITY,lenvima,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Lenvima (lenvatinib) is a multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of  thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.","February 13, 2015",Eisai Inc.,"Thyroid Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Endometrial Carcinoma","February 13, 2015",2015-02-13,lenvatinib,lenvatinib
SODIUM ZIRCONIUM CYCLOSILICATE,ORIG,1,AP,2018-05-18T00:00:00Z,NA,STANDARD,lokelma,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults.,"May 18, 2018",AstraZeneca,Hyperkalemia,"May 18, 2018",2018-05-18,sodium zirconium cyclosilicate,sodium
PALBOCICLIB,ORIG,1,AP,2015-02-03T00:00:00Z,NA,PRIORITY,ibrance,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Ibrance (palbociclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:","February 3, 2015",Pfizer Inc.,Breast Cancer,"February 3, 2015",2015-02-03,palbociclib,palbociclib
SAFINAMIDE MESYLATE,ORIG,1,AP,2017-03-21T00:00:00Z,NA,STANDARD,xadago,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s
disease (PD) experiencing “off” episodes. ","March 21, 2017",Newron Pharmaceuticals S.p.A.,Parkinson's Disease,"March 21, 2017",2017-03-21,safinamide,safinamide
PIMAVANSERIN TARTRATE,ORIG,1,AP,2016-04-29T00:00:00Z,NA,PRIORITY,nuplazid,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Nuplazid (pimavanserin) is a non-dopaminergic, selective serotonin inverse agonist (SSIA) for the treatment of psychosis associated with Parkinson’s disease. ","April 29, 2016",Acadia Pharmaceuticals Inc. ,Parkinson’s Disease Psychosis,"April 29, 2016",2016-04-29,pimavanserin,pimavanserin
ISAVUCONAZONIUM SULFATE,ORIG,1,AP,2015-03-06T00:00:00Z,NA,PRIORITY,cresemba,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cresemba (isavuconazonium) is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.,"March 6, 2015","Astellas Pharma US, Inc.",Invasive Aspergillosis; Invasive Mucormycosis,"March 6, 2015",2015-03-06,isavuconazonium,isavuconazonium
ARIPIPRAZOLE LAUROXIL,ORIG,1,AP,2015-10-05T00:00:00Z,NA,STANDARD,aristada,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,"Aristada (aripiprazole lauroxil) is an extended-release injectable atypical antipsychotic with one-month, six-week, and two-month dosing options for the treatment of schizophrenia. ","October 5, 2015",Alkermes plc ,Schizophrenia,"October 5, 2015",2015-10-05,aripiprazole lauroxil,aripiprazole
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE,ORIG,1,AP,2015-11-05T00:00:00Z,NA,STANDARD,genvoya,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,"Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or E/C/F/TAF) is an antiretroviral combination for the treatment of HIV infection.","November 5, 2015","Gilead Sciences, Inc.",HIV Infection,"November 5, 2015",2015-11-05,"elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or E/C/F/TAF",elvitegravir
SACUBITRIL; VALSARTAN,ORIG,1,AP,2015-07-07T00:00:00Z,NA,PRIORITY,entresto,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination indicated:,"July 7, 2015",Novartis Pharmaceuticals Corporation,Heart Failure,"July 7, 2015",2015-07-07,sacubitril and valsartan,sacubitril
CRISABOROLE,ORIG,1,AP,2016-12-14T00:00:00Z,NA,STANDARD,eucrisa,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Eucrisa (crisaborole) is a novel, non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis.","December 14, 2016","Pfizer, Inc.",Atopic Dermatitis,"December 14, 2016",2016-12-14,crisaborole,crisaborole
LATANOPROSTENE BUNOD,ORIG,1,AP,2017-11-02T00:00:00Z,NA,STANDARD,vyzulta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vyzulta (latanoprostene bunod) is a nitric oxide donating prostaglandin receptor agonist for the treatment of patients with open angle glaucoma or ocular hypertension.,"November 2, 2017","Valeant Pharmaceuticals International, Inc.","Glaucoma (Open Angle), Intraocular Hypertension","November 2, 2017",2017-11-02,latanoprostene bunod,latanoprostene
BARICITINIB,ORIG,1,AP,2018-05-31T00:00:00Z,NA,STANDARD,olumiant,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.,"May 31, 2018Company: Eli Lilly and ",Eli Lilly and Company and Incyte Corporation ,Rheumatoid Arthritis,"May 31, 2018",2018-05-31,baricitinib,baricitinib
SELEXIPAG,ORIG,1,AP,2015-12-21T00:00:00Z,NA,STANDARD,uptravi,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Uptravi (selexipag) is an oral prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension.,"December 21, 2015","Actelion Pharmaceuticals US, Inc.",Pulmonary Arterial Hypertension,"December 21, 2015",2015-12-21,selexipag,selexipag
TRABECTEDIN,ORIG,1,AP,2015-10-23T00:00:00Z,NA,PRIORITY,yondelis,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma.

","October 23, 2015","Janssen Biotech, Inc.",Soft Tissue Sarcoma,"October 23, 2015",2015-10-23,trabectedin,trabectedin
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE,ORIG,1,AP,2015-09-22T00:00:00Z,NA,STANDARD,lonsurf,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Lonsurf (tipiracil and trifluridine) is a thymidine phosphorylase inhibitor and nucleoside metabolic inhibitor combination indicated for the treatment of patients with previously treated metastatic colorectal cancer, and previously treated metastatic gastric or gastroesophageal junction adenocarcinoma.","September 22, 2015","Taiho Oncology, Inc.","Colorectal Cancer, Gastric Cancer","September 22, 2015",2015-09-22,tipiracil and trifluridine,tipiracil
LESINURAD,ORIG,1,AP,2015-12-22T00:00:00Z,NA,STANDARD,zurampic,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,Zurampic (lesinurad) is a URAT1 inhibitor indicated for the combination treatment of hyperuricemia associated with gout.,"December 22, 2015","Ironwood Pharmaceuticals, Inc.",Hyperuricemia Associated with Gout,"December 22, 2015",2015-12-22,lesinurad,lesinurad
MIDOSTAURIN,ORIG,2,AP,2017-04-28T00:00:00Z,NA,PRIORITY,rydapt,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Rydapt (midostaurin) is an oral, multi-targeted kinase inhibitor for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, and for the treatment of advanced systemic mastocytosis (SM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and mast cell leukemia.","April 28, 2017",Novartis,"Acute Myeloid Leukemia, Mastocytosis","April 28, 2017",2017-04-28,midostaurin,midostaurin
OBETICHOLIC ACID,ORIG,1,AP,2016-05-27T00:00:00Z,NA,PRIORITY,ocaliva,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Ocaliva (obeticholic acid) is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis.

","May 27, 2016","Intercept Pharmaceuticals, Inc.",Biliary Cirrhosis,"May 27, 2016",2016-05-27,obeticholic acid,obeticholic
NERATINIB MALEATE,ORIG,1,AP,2017-07-17T00:00:00Z,NA,STANDARD,nerlynx,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Nerlynx (neratinib) is a tyrosine kinase inhibitor for the extended adjuvant treatment of early-stage HER2-positive breast cancer.,"July 17, 2017","Puma Biotechnology, Inc.",Breast Cancer -- Adjuvant,"July 17, 2017",2017-07-17,neratinib,neratinib
FLUCICLOVINE F-18,ORIG,1,AP,2016-05-27T00:00:00Z,NA,PRIORITY,axumin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Axumin (fluciclovine F 18) a radioactive diagnostic agent indicated for positron emission
tomography (PET) imaging in men with suspected recurrent prostate cancer.","May 27, 2016","Blue Earth Diagnostics, Ltd.",Diagnostic,"May 27, 2016",2016-05-27,fluciclovine F 18,fluciclovine
OSIMERTINIB MESYLATE,ORIG,1,AP,2015-11-13T00:00:00Z,NA,PRIORITY,tagrisso,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Tagrisso (osimertinib) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) indicated for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer.

","November 13, 2015",AstraZeneca Pharmaceuticals,Non-Small Cell Lung Cancer,"November 13, 2015",2015-11-13,osimertinib,osimertinib
LIFITEGRAST,ORIG,1,AP,2016-07-11T00:00:00Z,NA,PRIORITY,xiidra,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease.,"July 11, 2016",Shire US Inc.,Dry Eye Disease,"July 11, 2016",2016-07-11,lifitegrast,lifitegrast
AMIFAMPRIDINE PHOSPHATE,ORIG,1,AP,2018-11-28T00:00:00Z,NA,PRIORITY,firdapse,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,"Firdapse (amifampridine phosphate) is a nonspecific, voltage-dependent, potassium (K+) channel blocker for the treatment of Lambert Eaton myasthenic syndrome (LEMS) in adults.","November 28, 2018","Catalyst Pharmaceuticals, Inc.",Lambert Eaton Myasthenic Syndrome,"November 28, 2018",2018-11-28,amifampridine phosphate,amifampridine
DEUTETRABENAZINE,ORIG,1,AP,2017-04-03T00:00:00Z,NA,STANDARD,austedo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor
indicated for the treatment of chorea associated with Huntington’s disease and the treatment of tardive dyskinesia.","April 3, 2017",Teva Pharmaceutical Industries Ltd.,"Huntington Disease, Tardive Dyskinesia","April 3, 2017",2017-04-03,deutetrabenazine,deutetrabenazine
DEFIBROTIDE SODIUM,ORIG,1,AP,2016-03-30T00:00:00Z,NA,PRIORITY,defitelio,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Defitelio (defibrotide sodium) is a deoxyribonucleic acid derivative anticoagulant for the treatment of patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).,"March 30, 2016",Jazz Pharmaceuticals plc,Hepatic Veno-Occlusive Disease,"March 30, 2016",2016-03-30,defibrotide sodium,defibrotide
URIDINE TRIACETATE,ORIG,1,AP,2015-09-04T00:00:00Z,NA,PRIORITY,xuriden,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Xuriden (uridine triacetate) is an orally administered pyrimidine analog uridine replacement product for the treatment of patients with hereditary orotic aciduria.,"September 4, 2015",Wellstat Therapeutics Corporation,Hereditary Orotic Aciduria,"September 4, 2015",2015-09-04,uridine triacetate,uridine
NETARSUDIL DIMESYLATE,ORIG,1,AP,2017-12-18T00:00:00Z,NA,STANDARD,rhopressa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,"Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension.

","December 18, 2017","Aerie Pharmaceuticals, Inc.",Glaucoma,"December 18, 2017",2017-12-18,netarsudil ophthalmic solution,netarsudil
LATANOPROST; NETARSUDIL DIMESYLATE,ORIG,1,AP,2019-03-12T00:00:00Z,NA,STANDARD,rocklatan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,"Rocklatan (netarsudil and latanoprost ophthalmic solution) is a fixed dose combination of the Rho kinase inhibitor netarsudil (Rhopressa) and the prostaglandin F2α analogue latanoprost (Xalatan), indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.","March 12, 2019","Aerie Pharmaceuticals, Inc.","Glaucoma (Open Angle), Intraocular Hypertension","March 12, 2019",2019-03-12,netarsudil and latanoprost ophthalmic solution,netarsudil
ELBASVIR; GRAZOPREVIR,ORIG,1,AP,2016-01-28T00:00:00Z,NA,PRIORITY,zepatier,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,"Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.","January 28, 2016","Merck & Co., Inc.",Chronic Hepatitis C,"January 28, 2016",2016-01-28,elbasvir and grazoprevir,elbasvir
ETELCALCETIDE,ORIG,1,AP,2017-02-07T00:00:00Z,NA,STANDARD,parsabiv,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.,"February 7, 2017",Amgen Inc.,Secondary Hyperparathyroidism,"February 7, 2017",2017-02-07,etelcalcetide,etelcalcetide
SOFOSBUVIR; VELPATASVIR,ORIG,1,AP,2016-06-28T00:00:00Z,NA,PRIORITY,epclusa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.,"June 28, 2016","Gilead Sciences, Inc.",Chronic Hepatitis C,"June 28, 2016",2016-06-28,sofosbuvir and velpatasvir,sofosbuvir
BETRIXABAN,ORIG,1,AP,2017-06-23T00:00:00Z,NA,PRIORITY,bevyxxa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.

","June 23, 2017",Portola Pharmaceuticals Inc.,Prevention of Venous Thromboembolism,"June 23, 2017",2017-06-23,betrixaban,betrixaban
ALECTINIB HYDROCHLORIDE,ORIG,1,AP,2015-12-11T00:00:00Z,NA,PRIORITY,alecensa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Alecensa (alectinib) is an oral, anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).","December 11, 2015","Genentech, Inc.",Non-Small Cell Lung Cancer,"December 11, 2015",2015-12-11,alectinib,alectinib
NIRAPARIB TOSYLATE,ORIG,1,AP,2017-03-27T00:00:00Z,NA,PRIORITY,zejula,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the treatment of patients with ovarian, fallopian tube, or primary peritoneal cancer.","March 27, 2017","Tesaro, Inc.","Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","March 27, 2017",2017-03-27,niraparib,niraparib
IXAZOMIB CITRATE,ORIG,1,AP,2015-11-20T00:00:00Z,NA,PRIORITY,ninlaro,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Ninlaro (ixazomib) is an oral proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.,"November 20, 2015Company: Takeda Pharmaceutical ",Takeda Pharmaceutical Company Limited,Multiple Myeloma,"November 20, 2015",2015-11-20,ixazomib,ixazomib
LIXISENATIDE,ORIG,1,AP,2016-07-27T00:00:00Z,NA,STANDARD,adlyxin,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Adlyxin (lixisenatide) is a once-daily prandial GLP-1
receptor agonist for the treatment of adults with type 2 diabetes
mellitus.","July 27, 2016",Sanofi,Diabetes Type 2,"July 27, 2016",2016-07-27,lixisenatide,lixisenatide
GALLIUM DOTATATE GA-68,ORIG,1,AP,2016-06-01T00:00:00Z,NA,PRIORITY,netspot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Netspot (gallium Ga 68 dotatate) is a radioactive diagnostic
agent indicated for use with positron emission tomography (PET) for
localization of somatostatin receptor positive neuroendocrine tumors","June 1, 2016","Advanced Accelerator Applications USA, Inc.",Diagnostic,"June 1, 2016",2016-06-01,gallium Ga 68 dotatate,gallium
VENETOCLAX,ORIG,1,AP,2016-04-11T00:00:00Z,NA,PRIORITY,venclexta,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor indicated:,"April 11, 2016",AbbVie Inc.,"Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia","April 11, 2016",2016-04-11,venetoclax,venetoclax
DELAFLOXACIN MEGLUMINE,ORIG,1,AP,2017-06-19T00:00:00Z,"Please see <a href=""https://www.fda.gov/STIC/"">www.fda.gov/STIC</a> for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.",PRIORITY,baxdela,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.,"June 19, 2017",Melinta Therapeutics,"Skin and Structure Infection, Pneumonia","June 19, 2017",2017-06-19,delafloxacin,delafloxacin
MIGALASTAT HYDROCHLORIDE,ORIG,1,AP,2018-08-10T00:00:00Z,NA,PRIORITY,galafold,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Galafold (migalastat) is an alpha-galactosidase A (alpha-Gal A) pharmacological
chaperone indicated for the treatment of adults with a confirmed diagnosis of
Fabry disease and an amenable galactosidase alpha gene variant.","August 10, 2018",Amicus Therapeutics,Fabry Disease,"August 10, 2018",2018-08-10,migalastat,migalastat
TECOVIRIMAT,ORIG,1,AP,2018-07-13T00:00:00Z,NA,PRIORITY,tpoxx,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TPOXX (tecovirimat) is an orthopoxvirus-specific antiviral indicated for the treatment of human smallpox disease.,"July 13, 2018","SIGA Technologies, Inc.",Smallpox,"July 13, 2018",2018-07-13,tecovirimat,tecovirimat
DEFLAZACORT,ORIG,1,AP,2017-02-09T00:00:00Z,NA,PRIORITY,emflaza,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne
muscular dystrophy (DMD) in patients 2 years of age and older.","February 9, 2017","PTC Therapeutics, Inc.",Duchenne Muscular Dystrophy,"February 9, 2017",2017-02-09,deflazacort,deflazacort
LUTETIUM DOTATATE LU-177,ORIG,1,AP,2018-01-26T00:00:00Z,NA,PRIORITY,lutathera,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. ,"January 26, 2018",Advanced Accelerator Applications S.A.,Gastroenteropancreatic Neuroendocrine Tumors,"January 26, 2018",2018-01-26,lutetium Lu 177 dotatate,lutetium
TRICLABENDAZOLE,ORIG,1,AP,2019-02-13T00:00:00Z,NA,PRIORITY,egaten,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,"Egaten (triclabendazole) is a benzimidazole anthelmintic indicated for the treatment of fascioliasis,  a neglected tropical disease (NTD) caused by liver flukes Fasciola hepatica and Fasciola gigantica.","February 13, 2019",Novartis,Fascioliasis,"February 13, 2019",2019-02-13,triclabendazole,triclabendazole
ABEMACICLIB,ORIG,1,AP,2017-09-28T00:00:00Z,NA,PRIORITY,verzenio,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Verzenio (abemaciclib) is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.
","September 28, 2017Company: Eli Lilly and ",Eli Lilly and Company,Breast Cancer,"September 28, 2017",2017-09-28,abemaciclib,abemaciclib
ABALOPARATIDE,ORIG,1,AP,2017-04-28T00:00:00Z,NA,STANDARD,tymlos,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Tymlos (abaloparatide) is a synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein) for the treatment of postmenopausal women with osteoporosis. ,"April 28, 2017","Radius Health, Inc.",Osteoporosis,"April 28, 2017",2017-04-28,abaloparatide,abaloparatide
PLECANATIDE,ORIG,1,AP,2017-01-19T00:00:00Z,NA,STANDARD,trulance,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Trulance (plecanatide) is a guanylate cyclase-C agonist for the treatment of chronic idiopathic constipation, and irritable bowel syndrome with constipation (IBS-C).","January 19, 2017",Synergy Pharmaceuticals Inc. ,"Constipation -- Chronic, Irritable Bowel Syndrome","January 19, 2017",2017-01-19,plecanatide,plecanatide
BRIGATINIB,ORIG,1,AP,2017-04-28T00:00:00Z,NA,PRIORITY,alunbrig,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell cancer (NSCLC) whose disease is resistant to crizotinib.
","April 28, 2017Company: Takeda Pharmaceutical ",Takeda Pharmaceutical Company Limited,Non-Small Cell Lung Cancer,"April 28, 2017",2017-04-28,brigatinib,brigatinib
TELOTRISTAT ETIPRATE,ORIG,1,AP,2017-02-28T00:00:00Z,NA,PRIORITY,xermelo,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Xermelo (telotristat ethyl) is an oral tryptophan hydroxylase inhibitor indicated for use in combination with somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.,"February 28, 2017","Lexicon Pharmaceuticals, Inc.",Carcinoid Syndrome Diarrhea,"February 28, 2017",2017-02-28,telotristat ethyl,telotristat
NALDEMEDINE TOSYLATE,ORIG,1,AP,2017-03-23T00:00:00Z,NA,STANDARD,symproic,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.,"March 23, 2017",Shionogi Inc.,Opioid-Induced Constipation,"March 23, 2017",2017-03-23,naldemedine,naldemedine
OZENOXACIN,ORIG,1,AP,2017-12-11T00:00:00Z,NA,STANDARD,xepi,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Xepi (ozenoxacin) is a topical non-fluorinated quinolone for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.,"December 11, 2017","Medimetriks Pharmaceuticals, Inc.",Impetigo,"December 11, 2017",2017-12-11,ozenoxacin,ozenoxacin
RIBOCICLIB SUCCINATE,ORIG,1,AP,2017-03-13T00:00:00Z,NA,PRIORITY,kisqali,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Kisqali (ribociclib) is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 indicated for the combination treatment of pre/perimenopausal or postmenopausal women with HR+/HER2- metastatic breast cancer.
","March 13, 2017",Novartis Pharmaceuticals Corporation,Breast Cancer,"March 13, 2017",2017-03-13,ribociclib,ribociclib
RUCAPARIB CAMSYLATE,ORIG,1,AP,2016-12-19T00:00:00Z,NA,PRIORITY,rubraca,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious BRCA mutation
(germline and/or somatic)-associated epithelial ovarian, fallopian tube,
or primary peritoneal cancer who have been treated with two or more
chemotherapies; and for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ","December 19, 2016","Clovis Oncology, Inc.",Ovarian Cancer,"December 19, 2016",2016-12-19,rucaparib,rucaparib
EDARAVONE,ORIG,1,AP,2017-05-05T00:00:00Z,NA,STANDARD,radicava,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Radicava (edaravone) is a free radical scavenger that relieves the effects of oxidative stress, a likely factor in the onset and progression of amyotrophic lateral sclerosis.","May 5, 2017",Mitsubishi Tanabe Pharma,Amyotrophic Lateral Sclerosis,"May 5, 2017",2017-05-05,edaravone,edaravone
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR,ORIG,1,AP,2017-07-18T00:00:00Z,NA,PRIORITY,vosevi,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,"Vosevi (sofosbuvir, velpatasvir and voxilaprevir or SOF/VEL/VOX) is a fixed-dose combination of a nucleotide analog NS5B polymerase inhibitor (SOF), a pangenotypic NS5A inhibitor (VEL), and a pangenotypic NS3/4A protease inhibitor (VOX) for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.","July 18, 2017","Gilead Sciences, Inc.",Chronic Hepatitis C,"July 18, 2017",2017-07-18,"sofosbuvir, velpatasvir and voxilaprevir or SOF/VEL/VOX",sofosbuvir
LOFEXIDINE HYDROCHLORIDE,ORIG,1,AP,2018-05-16T00:00:00Z,NA,PRIORITY,lucemyra,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.,"May 16, 2018",US WorldMeds,Opiate Withdrawal,"May 16, 2018",2018-05-16,lofexidine hydrochloride,lofexidine
VALBENAZINE TOSYLATE,ORIG,1,AP,2017-04-11T00:00:00Z,NA,PRIORITY,ingrezza,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor for the treatment of tardive dyskinesia.

","April 11, 2017","Neurocrine Biosciences, Inc.",Tardive Dyskinesia,"April 11, 2017",2017-04-11,valbenazine,valbenazine
FOSTAMATINIB DISODIUM,ORIG,1,AP,2018-04-17T00:00:00Z,NA,STANDARD,tavalisse,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).
","April 17, 2018","Rigel Pharmaceuticals, Inc.",Idiopathic (Immune) Thrombocytopenic Purpura,"April 17, 2018",2018-04-17,fostamatinib,fostamatinib
ANGIOTENSIN II ACETATE,ORIG,1,AP,2017-12-21T00:00:00Z,NA,PRIORITY,giapreza,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.,"December 21, 2017Company: La Jolla Pharmaceutical ",La Jolla Pharmaceutical Company,"Hypotension, Shock","December 21, 2017",2017-12-21,angiotensin II,angiotensin
SECNIDAZOLE,ORIG,1,AP,2017-09-15T00:00:00Z,NA,PRIORITY,solosec,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in the treatment of bacterial vaginosis (BV).,"September 15, 2017","Symbiomix Therapeutics, LLC",Bacterial Vaginosis,"September 15, 2017",2017-09-15,secnidazole,secnidazole
GLECAPREVIR; PIBRENTASVIR,ORIG,1,AP,2017-08-03T00:00:00Z,NA,PRIORITY,mavyret,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, indicated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C.","August 3, 2017",AbbVie Inc.,Chronic Hepatitis C,"August 3, 2017",2017-08-03,glecaprevir/pibrentasvir,glecaprevir
CEFIDEROCOL SULFATE TOSYLATE,ORIG,1,AP,2019-11-14T00:00:00Z,NA,PRIORITY,fetroja,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Fetroja (cefiderocol) is a siderophore cephalosporin indicated for the treatment of complicated urinary tract infections (cUTI) in patients with limited or no alternative treatment options.,"November 14, 2019","Shionogi & Co., Ltd.",Complicated Urinary Tract Infections,"November 14, 2019",2019-11-14,cefiderocol,cefiderocol
LUMATEPERONE,ORIG,1,AP,2019-12-20T00:00:00Z,NA,STANDARD,caplyta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Caplyta (lumateperone) is first-in-class antipsychotic for the treatment of schizophrenia.,"December 23, 2019","Intra-Cellular Therapies, Inc.",Schizophrenia,"December 23, 2019",2019-12-23,lumateperone,lumateperone
SARECYCLINE HYDROCHLORIDE,ORIG,1,AP,2018-10-01T00:00:00Z,NA,STANDARD,seysara,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.","October 1, 2018","Almirall, S.A.",Acne,"October 1, 2018",2018-10-01,sarecycline,sarecycline
NUSINERSEN SODIUM,ORIG,1,AP,2016-12-23T00:00:00Z,NA,PRIORITY,spinraza,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,"Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense
oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in  pediatric and adult patients.
","December 23, 2016",Biogen,Spinal Muscular Atrophy,"December 23, 2016",2016-12-23,nusinersen,nusinersen
ENASIDENIB MESYLATE,ORIG,1,AP,2017-08-01T00:00:00Z,NA,PRIORITY,idhifa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Idhifa (enasidenib) is a first-in-class, oral, targeted inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.","August 1, 2017",Celgene Corporation,Acute Myeloid Leukemia,"August 1, 2017",2017-08-01,enasidenib,enasidenib
ETHINYL ESTRADIOL; SEGESTERONE ACETATE,ORIG,1,AP,2018-08-10T00:00:00Z,NA,STANDARD,annovera,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Annovera (ethinyl estradiol and segesterone acetate) is an estrogen and progestin vaginal contraceptive system indicated to prevent pregnancy for up to a year.,"August 10, 2018",The Population Council,Contraception,"August 10, 2018",2018-08-10,ethinyl estradiol and segesterone acetate,ethinyl
SEMAGLUTIDE,ORIG,1,AP,2017-12-05T00:00:00Z,NA,STANDARD,ozempic,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment of adults with type 2 diabetes.,"December 5, 2017",Novo Nordisk,Diabetes Type 2,"December 5, 2017",2017-12-05,semaglutide,semaglutide
MEROPENEM; VABORBACTAM,ORIG,1,AP,2017-08-29T00:00:00Z,"Please see <a href=""https://www.fda.gov/STIC/"">www.fda.gov/STIC</a> for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.",PRIORITY,vabomere,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs).,"August 29, 2017","Chemo Research, S. L.",Chagas Disease,"August 29, 2017",2017-08-29,meropenem and vaborbactam,meropenem
ERTUGLIFLOZIN,ORIG,1,AP,2017-12-19T00:00:00Z,NA,STANDARD,steglatro,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to help improve glycemic control in adults with type 2 diabetes.,"December 19, 2017",Merck,Diabetes Type 2,"December 19, 2017",2017-12-19,ertugliflozin,ertugliflozin
OMADACYCLINE TOSYLATE,ORIG,1,AP,2018-10-02T00:00:00Z,NA,PRIORITY,nuzyra,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Nuzyra (omadacycline) is an aminomethylcycline tetracycline antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).,"October 2, 2018","Paratek Pharmaceuticals, Inc.","Skin and Structure Infection, Pneumonia","October 2, 2018",2018-10-02,omadacycline,omadacycline
SIPONIMOD FUMARIC ACID,ORIG,1,AP,2019-03-26T00:00:00Z,NA,PRIORITY,mayzent,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.","March 26, 2019",Novartis,Multiple Sclerosis,"March 26, 2019",2019-03-26,siponimod,siponimod
COPANLISIB DIHYDROCHLORIDE,ORIG,1,AP,2017-09-14T00:00:00Z,NA,PRIORITY,aliqopa,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).,"September 14, 2017","Bayer Healthcare Pharmaceuticals, Inc.",Follicular Lymphoma,"September 14, 2017",2017-09-14,copanlisib,copanlisib
LETERMOVIR,ORIG,1,AP,2017-11-08T00:00:00Z,NA,PRIORITY,prevymis,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.,"November 8, 2017","Merck & Co., Inc.",CMV Prophylaxis,"November 8, 2017",2017-11-08,letermovir,letermovir
PRUCALOPRIDE SUCCINATE,ORIG,1,AP,2018-12-14T00:00:00Z,NA,STANDARD,motegrity,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Motegrity (prucalopride) is a selective serotonin type 4 (5‑HT4) receptor agonist for the treatment of chronic idiopathic constipation (CIC) in adults.,"December 14, 2018",Shire plc,Chronic Idiopathic Constipation,"December 14, 2018",2018-12-14,prucalopride,prucalopride
AVATROMBOPAG MALEATE,ORIG,1,AP,2018-05-21T00:00:00Z,NA,PRIORITY,doptelet,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of:","May 21, 2018","Dova Pharmaceuticals, Inc.","Thrombocytopenia, Idiopathic (Immune) Thrombocytopenic Purpura","May 21, 2018",2018-05-21,avatrombopag,avatrombopag
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE,ORIG,1,AP,2018-02-07T00:00:00Z,NA,PRIORITY,biktarvy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) is an integrase strand transfer inhibitor and emtricitabine/tenofovir alafenamide (Descovy) combination for the treatment of HIV-1 infection in adults.","February 7, 2018","Gilead Sciences, Inc.",HIV Infection,"February 7, 2018",2018-02-07,"bictegravir, emtricitabine and tenofovir alafenamide",bictegravir
ACALABRUTINIB,ORIG,1,AP,2017-10-31T00:00:00Z,NA,PRIORITY,calquence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.","October 31, 2017",AstraZeneca,Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia,"October 31, 2017",2017-10-31,acalabrutinib,acalabrutinib
PLAZOMICIN SULFATE,ORIG,1,AP,2018-06-25T00:00:00Z,NA,PRIORITY,zemdri,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Zemdri (plazomicin) is an aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
","June 25, 2018","Achaogen, Inc.",Urinary Tract Infection,"June 25, 2018",2018-06-25,plazomicin,plazomicin
CANNABIDIOL,ORIG,1,AP,2018-06-25T00:00:00Z,Date of Approval; DEA Scheduling Not Complete,PRIORITY,epidiolex,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,"Epidiolex (cannabidiol) is a prescription pharmaceutical formulation of highly-purified, marijuana plant-derived cannabidiol (CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older.","June 25, 2018",GW Pharmaceuticals plc,"Lennox-Gastaut Syndrome, Dravet Syndrome","June 25, 2018",2018-06-25,cannabidiol,cannabidiol
ELAGOLIX SODIUM,ORIG,1,AP,2018-07-23T00:00:00Z,NA,PRIORITY,orilissa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Orilissa (elagolix) is an orally administered gonadotropin-releasing hormone (GnRH) antagonist for the management of moderate to severe pain associated with endometriosis.,"July 23, 2018","AbbVie, Inc.",Endometriosis,"July 23, 2018",2018-07-23,elagolix,elagolix
"IVACAFTOR; IVACAFTOR, TEZACAFTOR",ORIG,1,AP,2018-02-12T00:00:00Z,NA,PRIORITY,symdeko,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the CFTR) gene that is responsive to Symdeko.,"February 12, 2018",Vertex Pharmaceuticals Incorporated,Cystic Fibrosis,"February 12, 2018",2018-02-12,ivacaftor/tezacaftor tablets and ivacaftor tablets,ivacaftor
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE,ORIG,1,AP,2018-04-19T00:00:00Z,NA,STANDARD,akynzeo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Akynzeo (netupitant and palonosetron) is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).,"October 10, 2014",Helsinn Group,Nausea/Vomiting -- Chemotherapy Induced,"October 10, 2014",2014-10-10,netupitant and palonosetron,netupitant
ENCORAFENIB,ORIG,1,AP,2018-06-27T00:00:00Z,NA,STANDARD,braftovi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Braftovi (encorafenib) is a kinase inhibitor indicated, in combination with
binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","June 27, 2018",Array BioPharma Inc.,Melanoma -- Metastatic,"June 27, 2018",2018-06-27,encorafenib,encorafenib
BINIMETINIB,ORIG,1,AP,2018-06-27T00:00:00Z,NA,STANDARD,mektovi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Mektovi (binimetinib)  is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","June 27, 2018",Array BioPharma Inc.,Melanoma -- Metastatic,"June 27, 2018",2018-06-27,binimetinib,binimetinib
BREMELANOTIDE ACETATE,ORIG,1,AP,2019-06-21T00:00:00Z,NA,STANDARD,vyleesi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vyleesi  (bremelanotide) is a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.,"June 21, 2019","AMAG Pharmaceuticals, Inc.",Hypoactive Sexual Desire Disorder,"June 21, 2019",2019-06-21,bremelanotide,bremelanotide
REVEFENACIN,ORIG,1,AP,2018-11-09T00:00:00Z,NA,STANDARD,yupelri,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).,"November 9, 2018","Theravance Biopharma, Inc.",Chronic Obstructive Pulmonary Disease,"November 9, 2018",2018-11-09,revefenacin,revefenacin
GLASDEGIB MALEATE,ORIG,1,AP,2018-11-21T00:00:00Z,NA,PRIORITY,daurismo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Daurismo (glasdegib) is a hedgehog pathway inhibitor indicated for the combination treatment of adult patients ≥75 years with newly-diagnosed acute myeloid leukemia (AML).,"November 21, 2018",Pfizer Inc.,Acute Myeloid Leukemia,"November 21, 2018",2018-11-21,glasdegib,glasdegib
TAFENOQUINE SUCCINATE,ORIG,1,AP,2018-07-20T00:00:00Z,NA,PRIORITY,krintafel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of relapse) of Plasmodium vivax malaria.,"July 20, 2018",GlaxoSmithKline,Malaria,"July 20, 2018",2018-07-20,tafenoquine,tafenoquine
AFAMELANOTIDE,ORIG,1,AP,2019-10-08T00:00:00Z,NA,PRIORITY,scenesse,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Scenesse (afamelanotide) is a selective agonist of the melanocortin 1 receptor (MC1R) indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).,"October 8, 2019",Clinuvel Pharmaceuticals Ltd.,Prevention of Phototoxicity in Erythropoietic Protoporphyria,"October 8, 2019",2019-10-08,afamelanotide,afamelanotide
DORAVIRINE,ORIG,1,AP,2018-08-30T00:00:00Z,NA,STANDARD,pifeltro,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Pifeltro (doravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 infection.,"August 30, 2018",Merck,HIV Infection,"August 30, 2018",2018-08-30,doravirine,doravirine
BALOXAVIR MARBOXIL,ORIG,1,AP,2018-10-24T00:00:00Z,NA,PRIORITY,xofluza,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor for the treatment of   influenza (the flu) in people 12 years of age and older who have had flu symptoms for no more than 48 hours and who are otherwise healthy, or at high risk of developing flu-related complications.","October 24, 2018","Genentech, Inc.",Influenza,"October 24, 2018",2018-10-24,baloxavir marboxil,baloxavir
LAROTRECTINIB SULFATE,ORIG,1,AP,2018-11-26T00:00:00Z,NA,PRIORITY,vitrakvi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vitrakvi (larotrectinib) is an oral selective tropomyosin receptor kinase (TRK) inhibitor for the treatment solid tumors harboring NTRK-fusion proteins.,"November 26, 2018","Loxo Oncology, Inc.",TRK Fusion Cancers,"November 26, 2018",2018-11-26,larotrectinib,larotrectinib
MOXIDECTIN,ORIG,1,AP,2018-06-13T00:00:00Z,NA,PRIORITY,moxidectin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Moxidectin is a macrocyclic lactone anthelmintic medicine indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older.,"June 13, 2018",Medicines Development for Global Health,Onchocerciasis,"June 13, 2018",2018-06-13,onchocerciasis,onchocerciasis
LORLATINIB,ORIG,1,AP,2018-11-02T00:00:00Z,NA,PRIORITY,lorbrena,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).,"November 2, 2018",Pfizer Inc.,Non-Small Cell Lung Cancer,"November 2, 2018",2018-11-02,lorlatinib,lorlatinib
RIFAMYCIN SODIUM,ORIG,1,AP,2018-11-16T00:00:00Z,NA,PRIORITY,aemcolo,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,"Aemcolo (rifamycin) is a broad spectrum, orally non-absorbable antibiotic for the treatment of traveler’s diarrhea caused by noninvasive strains of Escherichia coli.","November 16, 2018","Cosmo Technologies, Ltd.",Traveler's Diarrhea,"November 16, 2018",2018-11-16,rifamycin,rifamycin
PATISIRAN SODIUM,ORIG,1,AP,2018-08-10T00:00:00Z,NA,PRIORITY,onpattro,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Onpattro (patisiran) is a small interfering ribonucleic acid (siRNA) therapeutic  for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR).,"August 10, 2018","Alnylam Pharmaceuticals, Inc.",Hereditary Transthyretin-Mediated Amyloidosis (hATTR),"August 10, 2018",2018-08-10,patisiran,patisiran
LUSUTROMBOPAG,ORIG,1,AP,2018-07-31T00:00:00Z,NA,PRIORITY,mulpleta,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.","July 31, 2018",Shionogi Inc.,Thrombocytopenia,"July 31, 2018",2018-07-31,lusutrombopag,lusutrombopag
APALUTAMIDE,ORIG,1,AP,2018-02-14T00:00:00Z,NA,PRIORITY,erleada,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of metastatic castration-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer.","February 14, 2018","Janssen Pharmaceuticals, Inc.",Prostate Cancer,"February 14, 2018",2018-02-14,apalutamide,apalutamide
ERAVACYCLINE DIHYDROCHLORIDE,ORIG,1,AP,2018-08-27T00:00:00Z,NA,PRIORITY,xerava,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Xerava (eravacycline) is a fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections.,"August 27, 2018","Tetraphase Pharmaceuticals, Inc.",Complicated Intra-Abdominal Infections,"August 27, 2018",2018-08-27,eravacycline,eravacycline
PITOLISANT HYDROCHLORIDE,ORIG,1,AP,2019-08-14T00:00:00Z,NA,PRIORITY,wakix,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,Wakix (pitolisant) is a histamine-3 (H₃) receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.,"August 14, 2019","Harmony Biosciences, LLC",Narcolepsy,"August 14, 2019",2019-08-14,pitolisant,pitolisant
DUVELISIB,ORIG,1,AP,2018-09-24T00:00:00Z,NA,PRIORITY,copiktra,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Copiktra (duvelisib) is a first-in-class, oral, dual phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor for the treatment relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).","September 24, 2018","Verastem, Inc.","Chronic Lymphocytic Leukemia, Follicular Lymphoma","September 24, 2018",2018-09-24,duvelisib,duvelisib
INOTERSEN SODIUM,ORIG,1,AP,2018-10-05T00:00:00Z,NA,PRIORITY,tegsedi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Tegsedi (inotersen) is an antisense oligonucleotide inhibitor of the transthyretin (TTR) protein for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ,"October 5, 2018","Ionis Pharmaceuticals, Inc.",Amyloidogenic Transthyretin Amyloidosis,"October 5, 2018",2018-10-05,inotersen,inotersen
IVOSIDENIB,ORIG,1,AP,2018-07-20T00:00:00Z,NA,PRIORITY,tibsovo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor for the treatment of patients with acute myeloid leukemia who have an IDH1 mutation.,"July 20, 2018","Agios Pharmaceuticals, Inc.",Acute Myeloid Leukemia,"July 20, 2018",2018-07-20,ivosidenib,ivosidenib
SOLRIAMFETOL,ORIG,1,AP,2019-03-20T00:00:00Z,Date of Approval; DEA Scheduling Not Complete,STANDARD,sunosi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).,"March 20, 2019",Jazz Pharmaceuticals plc,"Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome","March 20, 2019",2019-03-20,solriamfetol,solriamfetol
LASMIDITAN SUCCINATE,ORIG,1,AP,2019-10-11T00:00:00Z,NA,STANDARD,reyvow,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Reyvow (lasmiditan) is a serotonin (5-HT)1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.,"October 11, 2019Company: Eli Lilly and ",Eli Lilly and Company,Migraine,"October 11, 2019",2019-10-11,lasmiditan,lasmiditan
DACOMITINIB,ORIG,1,AP,2018-09-27T00:00:00Z,NA,PRIORITY,vizimpro,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Vizimpro (dacomitinib) is an oral, once-daily, irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor (TKI) indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R
substitution mutations as detected by an FDA-approved test.","September 27, 2018",Pfizer Inc.,Non-Small Cell Lung Cancer,"September 27, 2018",2018-09-27,dacomitinib,dacomitinib
GILTERITINIB FUMARATE,ORIG,1,AP,2018-11-28T00:00:00Z,NA,PRIORITY,xospata,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,"November 28, 2018",Astellas Pharma Inc.,Acute Myeloid Leukemia,"November 28, 2018",2018-11-28,gilteritinib,gilteritinib
BREXANOLONE,ORIG,1,AP,2019-03-19T00:00:00Z,NA,PRIORITY,zulresso,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA)
receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).","March 19, 2019",Sage Therapeutics,Postpartum Depression,"March 19, 2019",2019-03-19,brexanolone,brexanolone
TRIFAROTENE,ORIG,1,AP,2019-10-04T00:00:00Z,NA,STANDARD,aklief,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older.,"October 4, 2019",Galderma,Acne,"October 4, 2019",2019-10-04,trifarotene,trifarotene
TALAZOPARIB TOSYLATE,ORIG,1,AP,2018-10-16T00:00:00Z,NA,PRIORITY,talzenna,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Talzenna (talazoparib) is an oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.,"October 16, 2018",Pfizer Inc.,Breast Cancer,"October 16, 2018",2018-10-16,talazoparib,talazoparib
LEFAMULIN ACETATE,ORIG,1,AP,2019-08-19T00:00:00Z,NA,PRIORITY,xenleta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Xenleta (lefamulin) is a first-in-class, semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP).","August 19, 2019",Nabriva Therapeutics plc,Pneumonia,"August 19, 2019",2019-08-19,lefamulin,lefamulin
UPADACITINIB,ORIG,1,AP,2019-08-16T00:00:00Z,NA,PRIORITY,rinvoq,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe rheumatoid arthritis.,"August 16, 2019",AbbVie Inc.,Rheumatoid Arthritis,"August 16, 2019",2019-08-16,upadacitinib,upadacitinib
UBROGEPANT,ORIG,1,AP,2019-12-23T00:00:00Z,NA,STANDARD,ubrelvy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Ubrelvy (ubrogepant) is a potent, orally-administered CGRP receptor antagonist for the acute treatment of migraine.","December 23, 2019",Allergan plc,Migraine,"December 23, 2019",2019-12-23,ubrogepant,ubrogepant
TENAPANOR HYDROCHLORIDE,ORIG,1,AP,2019-09-12T00:00:00Z,NA,STANDARD,ibsrela,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).","September 12, 2019","Ardelyx, Inc",Irritable Bowel Syndrome,"September 12, 2019",2019-09-12,tenapanor,tenapanor
PEXIDARTINIB HYDROCHLORIDE,ORIG,1,AP,2019-08-02T00:00:00Z,NA,PRIORITY,turalio,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.,"August 2, 2019Company: Daiichi Sankyo ","Daiichi Sankyo Company, Limited",Tenosynovial Giant Cell Tumor,"August 2, 2019",2019-08-02,pexidartinib,pexidartinib
TAZAROTENE,ORIG,1,AP,2019-12-18T00:00:00Z,NA,STANDARD,arazlo,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Arazlo (tazarotene) is a lotion formulation of the approved retinoid tazarotene for the topical treatment of acne vulgaris in patients 9 years of age and older.,"December 18, 2019",Bausch Health Companies Inc.,Acne,"December 18, 2019",2019-12-18,tazarotene,tazarotene
GOLODIRSEN,ORIG,1,AP,2019-12-12T00:00:00Z,NA,PRIORITY,vyondys 53,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vyondys 53 (golodirsen) is a phosphordiamidate morpholino oligimer for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping.,"December 12, 2019","Sarepta Therapeutics, Inc.",Duchenne Muscular Dystrophy,"December 12, 2019",2019-12-12,golodirsen,golodirsen
TAFAMIDIS MEGLUMINE,ORIG,1,AP,2019-05-03T00:00:00Z,NA,PRIORITY,vyndaqel,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.,"May 3, 2019",Pfizer Inc.,Cardiomyopathy of Transthyretin-Mediated Amyloidosis,"May 3, 2019",2019-05-03,tafamidis meglumine,tafamidis
ERDAFITINIB,ORIG,1,AP,2019-04-12T00:00:00Z,NA,PRIORITY,balversa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.","April 12, 2019","Janssen Pharmaceuticals, Inc.",Urothelial Carcinoma,"April 12, 2019",2019-04-12,erdafitinib,erdafitinib
LEMBOREXANT,ORIG,1,AP,2019-12-20T00:00:00Z,NA,STANDARD,dayvigo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia.,"December 20, 2019","Eisai Co., Ltd.",Insomnia,"December 20, 2019",2019-12-20,lemborexant,lemborexant
DAROLUTAMIDE,ORIG,1,AP,2019-07-30T00:00:00Z,NA,PRIORITY,nubeqa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).,"July 30, 2019",Bayer,Prostate Cancer,"July 30, 2019",2019-07-30,darolutamide,darolutamide
GIVOSIRAN SODIUM,ORIG,1,AP,2019-11-20T00:00:00Z,NA,PRIORITY,givlaari,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Givlaari (givosiran) is an aminolevulinate synthase 1-directed small interfering RNA (siRNA) indicated for the treatment of adults with acute hepatic porphyria (AHP).,"November 20, 2019","Alnylam Pharmaceuticals, Inc.",Acute Hepatic Porphyria,"November 20, 2019",2019-11-20,givosiran,givosiran
"ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR",ORIG,1,AP,2019-10-21T00:00:00Z,NA,PRIORITY,trikafta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,"October 21, 2019",Vertex Pharmaceuticals Incorporated,Cystic Fibrosis,"October 21, 2019",2019-10-21,elexacaftor/tezacaftor/ivacaftor and ivacaftor,elexacaftor
SELINEXOR,ORIG,1,AP,2019-07-03T00:00:00Z,NA,PRIORITY,xpovio,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Xpovio (selinexor) is a first in class Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist for the treatment of patients adult patients with relapsed or refractory multiple myeloma (RRMM).,"July 3, 2019",Karyopharm Therapeutics Inc.,Multiple Myeloma,"July 3, 2019",2019-07-03,selinexor,selinexor
FERRIC MALTOL,ORIG,1,AP,2019-07-25T00:00:00Z,NA,STANDARD,accrufer,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Accrufer (ferric maltol) is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults.,"July 25, 2019",Shield Therapeutics plc,Iron Deficiency,"July 25, 2019",2019-07-25,ferric maltol,ferric
FEDRATINIB HYDROCHLORIDE,ORIG,1,AP,2019-08-16T00:00:00Z,NA,PRIORITY,inrebic,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.,"August 16, 2019",Celgene Corporation,Myelofibrosis,"August 16, 2019",2019-08-16,fedratinib,fedratinib
ALPELISIB,ORIG,1,AP,2019-05-24T00:00:00Z,NA,PRIORITY,piqray,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the
treatment of postmenopausal women, and men, with HR positive, HER2-negative,
PIK3CA-mutated breast cancer.","May 24, 2019",Novartis,Breast Cancer,"May 24, 2019",2019-05-24,alpelisib,alpelisib
ENTRECTINIB,ORIG,1,AP,2019-08-15T00:00:00Z,NA,PRIORITY,rozlytrek,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Rozlytrek (entrectinib) is a selective tyrosine kinase inhibitor for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer and neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors.","August 15, 2019","Genentech, Inc.","Solid Tumors, Non-Small Cell Lung Cancer","August 15, 2019",2019-08-15,entrectinib,entrectinib
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ,ORIG,1,AP,2019-07-16T00:00:00Z,NA,PRIORITY,recarbrio,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Recarbrio (imipenem, cilastatin, and relebactam) is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI).","July 16, 2019",Merck,"Urinary Tract Infection, Intraabdominal Infection","July 16, 2019",2019-07-16,"imipenem, cilastatin, and relebactam",imipenem
CENOBAMATE,ORIG,1,AP,2019-11-21T00:00:00Z,NA,STANDARD,xcopri,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients.,"November 21, 2019","SK Life Science, Inc.",Seizures,"November 21, 2019",2019-11-21,cenobamate,cenobamate
PRETOMANID,ORIG,1,AP,2019-08-14T00:00:00Z,NA,PRIORITY,pretomanid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Pretomanid is a nitroimidazooxazine antimycobacterial indicated for use in combination with bedaquiline and linezolid (the BPaL regimen) for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).","August 14, 2019",TB Alliance,Tuberculosis -- Resistant,"August 14, 2019",2019-08-14,the BPaL regimen,the
VOXELOTOR,ORIG,1,AP,2019-11-25T00:00:00Z,NA,PRIORITY,oxbryta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD).","November 25, 2019","Global Blood Therapeutics, Inc.",Sickle Cell Anemia,"November 25, 2019",2019-11-25,voxelotor,voxelotor
ZANUBRUTINIB,ORIG,1,AP,2019-11-14T00:00:00Z,NA,PRIORITY,brukinsa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Brukinsa (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,"November 14, 2019","BeiGene, Ltd.",Mantle Cell Lymphoma,"November 14, 2019",2019-11-14,zanubrutinib,zanubrutinib
IDARUCIZUMAB,ORIG,1,AP,2015-10-16T00:00:00Z,NA,PRIORITY,praxbind,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,Praxbind (idarucizumab) is a humanized monoclonal antibody fragment (Fab) indicated as a specific reversal agent for the anticoagulant effect of dabigatran (Pradaxa).,"October 16, 2015","Boehringer Ingelheim Pharmaceuticals, Inc.",Reversal Agent for Pradaxa,"October 16, 2015",2015-10-16,idarucizumab,idarucizumab
DACLIZUMAB,ORIG,1,AP,2016-05-27T00:00:00Z,NA,STANDARD,zinbryta,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).,"May 27, 2016","AbbVie, Inc. and Biogen",Multiple Sclerosis,"May 27, 2016",2016-05-27,daclizumab,daclizumab
BRODALUMAB,ORIG,1,AP,2017-02-15T00:00:00Z,NA,STANDARD,siliq,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.,"February 15, 2017","Valeant Pharmaceuticals International, Inc.",Plaque Psoriasis,"February 15, 2017",2017-02-15,brodalumab,brodalumab
RESLIZUMAB,ORIG,1,AP,2016-03-23T00:00:00Z,NA,STANDARD,cinqair,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,Cinqair (reslizumab) is an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with eosinophilic asthma.,"March 23, 2016",Teva Pharmaceutical Industries Ltd.,Asthma,"March 23, 2016",2016-03-23,reslizumab,reslizumab
ATEZOLIZUMAB,ORIG,1,AP,2016-05-18T00:00:00Z,NA,PRIORITY,tecentriq,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and small cell lung cancer (SCLC).","May 18, 2016","Genentech, Inc.","Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Small Cell Lung Cancer","May 18, 2016",2016-05-18,atezolizumab,atezolizumab
ELOTUZUMAB,ORIG,1,AP,2015-11-30T00:00:00Z,NA,PRIORITY,empliciti,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated for the combination treatment of patients with multiple myeloma.,"November 30, 2015Company: Bristol-Myers Squibb ",Bristol-Myers Squibb Company and AbbVie,Multiple Myeloma,"November 30, 2015",2015-11-30,elotuzumab,elotuzumab
DARATUMUMAB,ORIG,1,AP,2015-11-16T00:00:00Z,NA,PRIORITY,darzalex,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma.,"November 16, 2015","Janssen Biotech, Inc.",Multiple Myeloma,"November 16, 2015",2015-11-16,daratumumab,daratumumab
SARILUMAB,ORIG,1,AP,2017-05-22T00:00:00Z,NA,STANDARD,kevzara,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Kevzara (sarilumab) is an interleukin-6 receptor (IL-6R) antibody for the treatment of adults with rheumatoid arthritis.,"May 22, 2017","Sanofi and Regeneron Pharmaceuticals, Inc.",Rheumatoid Arthritis,"May 22, 2017",2017-05-22,sarilumab,sarilumab
OLARATUMAB,ORIG,1,AP,2016-10-19T00:00:00Z,NA,PRIORITY,lartruvo,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).,"October 19, 2016Company: Eli Lilly and ",Eli Lilly and Company,Soft Tissue Sarcoma,"October 19, 2016",2016-10-19,olaratumab,olaratumab
INOTUZUMAB OZOGAMICIN,ORIG,1,AP,2017-08-17T00:00:00Z,NA,PRIORITY,besponsa,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,"Besponsa (inotuzumab ozogamicin) is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).




","August 17, 2017",Pfizer Inc.,Acute Lymphoblastic Leukemia,"August 17, 2017",2017-08-17,inotuzumab ozogamicin,inotuzumab
BEZLOTOXUMAB,ORIG,1,AP,2016-10-21T00:00:00Z,NA,PRIORITY,zinplava,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Zinplava (bezlotoxumab) is a selective, fully-human, monoclonal antibody that binds to Clostridium difficile toxin B, indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older.","October 21, 2016","Merck & Co., Inc.",Prevention of Clostridium Difficile Infection Recurrence,"October 21, 2016",2016-10-21,bezlotoxumab,bezlotoxumab
VESTRONIDASE ALFA-VJBK,ORIG,1,AP,2017-11-15T00:00:00Z,NA,PRIORITY,mepsevii,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Mepsevii (vestronidase alfa) is a recombinant human lysosomal beta glucuronidase
indicated for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).","November 15, 2017","Ultragenyx Pharmaceutical, Inc.",Mucopolysaccharidosis Type VII,"November 15, 2017",2017-11-15,vestronidase alfa,vestronidase
AVELUMAB,ORIG,1,AP,2017-03-23T00:00:00Z,NA,PRIORITY,bavencio,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody
indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC); patients with advanced or metastatic urothelial carcinoma; and in combination with axitinib for patients with advanced renal cell carcinoma.","March 23, 2017",EMD Serono Inc.,"Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma","March 23, 2017",2017-03-23,avelumab,avelumab
MOGAMULIZUMAB-KPKC,ORIG,1,AP,2018-08-08T00:00:00Z,NA,PRIORITY,poteligeo,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,"Poteligeo (mogamulizumab-kpkc) is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL).
","August 8, 2018","Kyowa Hakko Kirin Co., Ltd.",Mycosis Fungoides; Sézary Syndrome,"August 8, 2018",2018-08-08,mogamulizumab-kpkc,mogamulizumab
CERLIPONASE ALFA,ORIG,1,AP,2017-04-27T00:00:00Z,NA,PRIORITY,brineura,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Brineura (cerliponase alfa) is an enzyme replacement therapy for the restoration of tripeptidyl peptidase-1 (TPP1) enzyme activity in patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), or TPP1 deficiency, a form of Batten disease.","April 27, 2017",BioMarin Pharmaceutical Inc.,CLN2 Disease,"April 27, 2017",2017-04-27,cerliponase alfa,cerliponase
OCRELIZUMAB,ORIG,1,AP,2017-03-28T00:00:00Z,NA,PRIORITY,ocrevus,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Ocrevus (ocrelizumab) is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. Ocrevus is indicated as a treatment for both relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis.","March 28, 2017","Genentech, Inc.",Multiple Sclerosis,"March 28, 2017",2017-03-28,ocrelizumab,ocrelizumab
DUPILUMAB,ORIG,1,AP,2017-03-28T00:00:00Z,NA,PRIORITY,dupixent,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.","March 28, 2017","Sanofi  and Regeneron Pharmaceuticals, Inc.","Atopic Dermatitis, Asthma","March 28, 2017",2017-03-28,dupilumab,dupilumab
GUSELKUMAB,ORIG,1,AP,2017-07-13T00:00:00Z,NA,PRIORITY,tremfya,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,"Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for
systemic therapy or phototherapy.","July 13, 2017","Janssen Biotech, Inc.",Plaque Psoriasis,"July 13, 2017",2017-07-13,guselkumab,guselkumab
ROMOSOZUMAB-AQQG,ORIG,1,AP,2019-04-09T00:00:00Z,NA,STANDARD,evenity,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.,"April 9, 2019",Amgen Inc.,Osteoporosis,"April 9, 2019",2019-04-09,romosozumab,romosozumab
GALCANEZUMAB-GNLM,ORIG,1,AP,2018-09-27T00:00:00Z,NA,STANDARD,emgality,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,"Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine, and for the treatment of episodic cluster headache.","September 27, 2018Company: Eli Lilly and ",Eli Lilly and Company,"Migraine Prophylaxis, Cluster Headache","September 27, 2018",2018-09-27,galcanezumab-gnlm,galcanezumab
IBALIZUMAB-UIYK,ORIG,1,AP,2018-03-06T00:00:00Z,NA,PRIORITY,trogarzo,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.,"March 6, 2018",TaiMed Biologics USA Corp.,HIV Infection,"March 6, 2018",2018-03-06,ibalizumab-uiyk,ibalizumab
TILDRAKIZUMAB-ASMN,ORIG,1,AP,2018-03-20T00:00:00Z,NA,STANDARD,ilumya,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,"Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.","March 20, 2018",Sun Pharmaceutical Industries Ltd.,Plaque Psoriasis,"March 20, 2018",2018-03-20,tildrakizumab-asmn,tildrakizumab
BUROSUMAB-TWZA,ORIG,1,AP,2018-04-17T00:00:00Z,NA,PRIORITY,crysvita,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody for the treatment of x-linked hypophosphatemia (XLH).,"April 17, 2018",Ultragenyx Pharmaceutical Inc.,X-Linked Hypophosphatemia,"April 17, 2018",2018-04-17,burosumab-twza,burosumab
DURVALUMAB,ORIG,1,AP,2017-05-01T00:00:00Z,NA,PRIORITY,imfinzi,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,Imfinzi (durvalumab) is an anti-PD-L1 (programmed death ligand-1) human monoclonal antibody for the treatment of patients with metastatic urothelial carcinoma and for the treatment of patients with unresectable non-small cell lung cancer that has not progressed after chemoradiation.,"May 1, 2017",AstraZeneca,"Urothelial Carcinoma, Non-Small Cell Lung Cancer","May 1, 2017",2017-05-01,durvalumab,durvalumab
BENRALIZUMAB,ORIG,1,AP,2017-11-14T00:00:00Z,NA,STANDARD,fasenra,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,FALSE,Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.,"November 14, 2017",AstraZeneca,Asthma,"November 14, 2017",2017-11-14,benralizumab,benralizumab
ERENUMAB-AOOE,ORIG,1,AP,2018-05-17T00:00:00Z,NA,STANDARD,aimovig,NA,NA,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,"Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.
","May 17, 2018",Amgen Inc.,Migraine Prophylaxis,"May 17, 2018",2018-05-17,erenumab-aooe,erenumab
PEGVALIASE-PQPZ,ORIG,1,AP,2018-05-24T00:00:00Z,NA,PRIORITY,palynziq,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria.,"May 24, 2018",BioMarin Pharmaceutical Inc.,Phenylketonuria,"May 24, 2018",2018-05-24,pegvaliase-pqpz,pegvaliase
EMICIZUMAB,ORIG,1,AP,2017-11-16T00:00:00Z,NA,PRIORITY,hemlibra,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody
indicated to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.","November 16, 2017","Genentech, Inc.","Hemophilia A with Inhibitors, Hemophilia A","November 16, 2017",2017-11-16,emicizumab-kxwh,emicizumab
PRABOTULINUMTOXINA-XVFS,ORIG,1,AP,2019-02-01T00:00:00Z,NA,STANDARD,jeuveau,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Jeuveau (prabotulinumtoxinA) is a proprietary 900 kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines.,"February 1, 2019","Evolus, Inc.",Glabellar Lines,"February 1, 2019",2019-02-01,prabotulinumtoxinA,prabotulinumtoxinA
FREMANEZUMAB-VFRM,ORIG,1,AP,2018-09-14T00:00:00Z,NA,PRIORITY,ajovy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Ajovy (fremanezumab) is a fully-humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand indicated for the preventive treatment of migraine.,"September 14, 2018",Teva Pharmaceutical Industries Ltd.,Migraine Prophylaxis,"September 14, 2018",2018-09-14,fremanezumab,fremanezumab
LANADELUMAB (SHP643),ORIG,1,AP,2018-08-23T00:00:00Z,NA,PRIORITY,takhzyro,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Takhzyro (lanadelumab-flyo) is a plasma kallikrein inhibitor (monoclonal antibody) for the prevention of angioedema attacks in patients with hereditary angioedema.,"August 23, 2018",Shire plc,Hereditary Angioedema,"August 23, 2018",2018-08-23,lanadelumab-flyo,lanadelumab
ELAPEGADEMASE-LVLR,ORIG,1,AP,2018-10-05T00:00:00Z,NA,PRIORITY,revcovi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the
treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID).","October 5, 2018","Leadiant Biosciences, Inc.",Adenosine Deaminase Severe Combined Immune,"October 5, 2018",2018-10-05,elapegademase-lvlr,elapegademase
CENEGERMIN-BKBJ,ORIG,1,AP,2018-08-22T00:00:00Z,NA,PRIORITY,oxervate,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,Oxervate (cenegermin) is a recombinant human nerve growth factor (rhNGF) ophthalmic solution indicated for the treatment of neurotrophic keratitis.,"August 22, 2018",Dompé farmaceutici SpA,Neurotrophic Keratitis,"August 22, 2018",2018-08-22,cenegermin,cenegermin
CEMIPLIMAB-RWLC,ORIG,1,AP,2018-09-28T00:00:00Z,NA,PRIORITY,libtayo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody
indicated for the treatment of patients with metastatic cutaneous squamous
cell carcinoma (CSCC).","September 28, 2018",Sanofi,Squamous Cell Carcinoma,"September 28, 2018",2018-09-28,cemiplimab-rwlc,cemiplimab
CALASPARGASE PEGOL-MKNL,ORIG,1,AP,2018-12-20T00:00:00Z,NA,STANDARD,asparlas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Asparlas (calaspargase pegol-mknl) is an asparagine specific enzyme indicated as a component
of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia.","December 20, 2018",Servier Pharmaceuticals LLC,Acute Lymphoblastic Leukemia,"December 20, 2018",2018-12-20,calaspargase pegol-mknl,calaspargase
MOXETUMOMAB PASUDOTOX-TDFK,ORIG,1,AP,2018-09-13T00:00:00Z,NA,PRIORITY,lumoxiti,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Lumoxiti  (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia.,"September 13, 2018",AstraZeneca and MedImmune,Hairy Cell Leukemia,"September 13, 2018",2018-09-13,moxetumomab pasudotox-tdfk,moxetumomab
RISANKIZUMAB-RZAA,ORIG,1,AP,2019-04-23T00:00:00Z,NA,STANDARD,skyrizi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.,"April 23, 2019",AbbVie Inc.,Plaque Psoriasis,"April 23, 2019",2019-04-23,risankizumab-rzaa,risankizumab
EMAPALUMAB-LZSG,ORIG,1,AP,2018-11-20T00:00:00Z,NA,PRIORITY,gamifant,NA,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,Gamifant (emapalumab-lzsg) is an interferon gamma (IFNγ) blocking antibody for the treatment of patients with primary hemophagocytic lymphohistiocytosis (HLH).,"November 20, 2018",Novimmune SA,Hemophagocytic Lymphohistiocytosis,"November 20, 2018",2018-11-20,emapalumab-lzsg,emapalumab
RAVULIZUMAB-CWVZ,ORIG,1,AP,2018-12-21T00:00:00Z,NA,PRIORITY,ultomiris,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Ultomiris (ravulizumab-cwvz) is a long-acting C5 complement inhibitor for:,"December 21, 2018","Alexion Pharmaceuticals, Inc.","Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome","December 21, 2018",2018-12-21,ravulizumab-cwvz,ravulizumab
CAPLACIZUMAB-YHDP,ORIG,1,AP,2019-02-06T00:00:00Z,NA,PRIORITY,cablivi,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cablivi (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment
indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","February 6, 2019",Ablynx NV,Acquired Thrombotic Thrombocytopenic Purpura,"February 6, 2019",2019-02-06,caplacizumab-yhdp,caplacizumab
TAGRAXOFUSP-ERZS,ORIG,1,AP,2018-12-21T00:00:00Z,NA,PRIORITY,elzonris,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Elzonris (tagraxofusp-erzs) is a CD123-directed cytotoxin for the treatment of blastic
plasmacytoid dendritic cell neoplasm (BPDCN).","December 21, 2018","Stemline Therapeutics, Inc.",Blastic Plasmacytoid Dendritic Cell Neoplasm,"December 21, 2018",2018-12-21,tagraxofusp-erzs,tagraxofusp
POLATUZUMAB VEDOTIN-PIIQ,ORIG,1,AP,2019-06-10T00:00:00Z,NA,PRIORITY,polivy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Polivy (polatuzumab vedotin-piiq) is a CD79b-directed antibody–drug conjugate indicated in
combination with bendamustine and rituximab for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, who have received at least two prior therapies.","June 10, 2019","Genentech, Inc.",Diffuse Large B-Cell Lymphoma,"June 10, 2019",2019-06-10,polatuzumab vedotin-piiq,polatuzumab
brolucizumab-dbll,ORIG,1,AP,2019-10-07T00:00:00Z,NA,PRIORITY,beovu,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Beovu (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor
indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).","October 7, 2019",Novartis,Macular Degeneration,"October 7, 2019",2019-10-07,brolucizumab-dbll,brolucizumab
CRIZANLIZUMAB-TMCA,ORIG,1,AP,2019-11-15T00:00:00Z,NA,PRIORITY,adakveo,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Adakveo (crizanlizumab-tmca) is a P-selectin inhibitor for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD).,"November 15, 2019",Novartis,Prevention of Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease,"November 15, 2019",2019-11-15,crizanlizumab-tmca,crizanlizumab
LUSPATERCEPT-AAMT,ORIG,1,AP,2019-11-08T00:00:00Z,NA,PRIORITY,reblozyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent (EMA) for the treatment of transfusion-dependent beta-thalassemia-associated anemia.,"November 8, 2019",Celgene Corporation,Beta-Thalassemia-Associated Anemia,"November 8, 2019",2019-11-08,luspatercept-aamt,luspatercept
ENFORTUMAB VEDOTIN-EJFV,ORIG,1,AP,2019-12-18T00:00:00Z,NA,PRIORITY,padcev,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Padcev (enfortumab vedotin-ejfv) is a Nectin-4 targeted antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or metastatic urothelial cancer.,"December 18, 2019",Astellas and Seattle Genetics,Urothelial Carcinoma,"December 18, 2019",2019-12-18,enfortumab vedotin-ejfv,enfortumab
FAM-TRASTUZUMAB DERUXTECAN-NXKI,ORIG,1,AP,2019-12-20T00:00:00Z,NA,PRIORITY,enhertu,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor
conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.","December 20, 2019Company: AstraZeneca and Daiichi Sankyo ","AstraZeneca and Daiichi Sankyo Company, Limited",Breast Cancer,"December 20, 2019",2019-12-20,fam-trastuzumab deruxtecan-nxki,fam
